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ABSTRACT 
      
Purpose: To assess whether the provision of a pedometer and exercise diary could significantly 
increase the activity levels of phase II cardiac rehabilitation program patients on the days they 
did not attend the program. Methods: Seventy patients (53 males, 17 females, age of 68 
plus/minus 9 yrs, BMI 29.0 plus/minus 6.1 kg/m2 participated in the study. During their first visit 
to a phase II CRP, patients were assigned to one of two groups. Control patients were given a 
blinded pedometer (n = 34), while experimental subjects received a pedometer that they could 
view (n = 36) as well as an exercise diary to record their daily step counts. Control patients wore 
the pedometer during all of their waking hours throughout phase II CRP enrollment and were 
encouraged to increase their overall activity levels in accordance with standard level of care. The 
baseline activity patterns of were determined during their first week of phase II CRP enrollment. 
Patients in the experimental group were encouraged to gradually increase their step counts on the 
days (Tuesday, Thursday, Saturday and Sunday; i.e., non-CRP days) they did not attend phase II 
CRP gradually until they were accumulating 2,000 steps/day above their baseline levels. Two 
sample t-tests were used to compare the baseline physical characteristics between genders as 
well as the control and experimental groups. Mean weekly step counts for both groups were 
compared based on overall and aerobic steps counts accumulated on CRP and non-CRP days 
using 2 times 7 repeated-measures ANOVAs. Results: At baseline, men took more overall steps 
than women and all patients took more steps on days they attended the phase II CRP, versus days 
they did not. There was a significant effect (p < 0.0001) of group assignment and time for overall 
and aerobic step counts on non-CRP days; as the experimental patients took significantly more 
steps and increased their step counts at a faster rate than the control patients. There was no 
significant interaction on CRP days as both groups significantly increased their overall and 
aerobic steps counts. Conclusion: Phase II CRP patients who used a pedometer and exercise 
diary significantly increased their overall and aerobic steps counts on CRP and non-CRP days, to 
a greater extent than patients who received usual care. Thus, pedometers can be used to increase 
the physical activity levels of phase II CRP patients.  
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CHAPTER I: INTRODUCTION
 1 
     Healthy People 2010 identified physical activity as one of the ten leading health indicators for 
American adults (186). In 2008, the federal government issued its initial physical activity 
guidelines for Americans. Specifically, it was recommended that healthy individuals accumulate 
at least 150 minutes per week of moderate intensity physical activity to obtain the majority of 
health benefits from exercise. Older adults with chronic conditions, who cannot meet this activity 
level, should be as physically active as their personal functional capacity and health conditions 
permit (124).  
     Physical inactivity is associated with an increased incidence of various chronic conditions 
including cardiovascular, metabolic, orthopedic and mental diseases and results in approximately 
250,000 premature deaths each year (10). There are numerous cross sectional, prospective and 
clinically randomized trials that indicate that regular physical activity is associated with positive 
health related outcomes (11). Yet an estimated 74% of U.S. adults do not perform 30 minutes of 
moderate leisure time physical activity on most days of the week, and about 27% are completely 
sedentary. Age demonstrates an inverse relationship with the percentage of individuals attaining 
the physical activity recommendations, with those 65 years and older demonstrating the least 
activity (125). This trend is sustained whether activity levels are self-reported or objectively 
monitored (e.g., subjects’ activity levels are assessed with accelerometers or pedometers) (100, 
148, 176).  
     Coronary heart disease (CHD) is one of the most common cardiovascular diseases, especially 
among seniors, as it currently affects 16 million Americans. Furthermore, it is the leading cause 
of death for adult males and females, contributing to over 600,000 fatalities annually. More than 
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1.2 million acute myocardial infarctions (MI) occur annually and it is estimated that 
approximately 15 years of life are lost due to the typical MI (132). 
     Research over the past 55 years has shown that regular physical activity reduces the 
occurrence of CHD. In 1952, Morris et al. (108) reported that the rate of CHD was lower in more 
active bus conductors versus sedentary bus drivers. Subsequent epidemiological studies noted an 
inverse relationship between caloric expenditure and heart attack risk as well as cardiorespiratoy 
fitness (CRF), an outcome of physical activity, and the prevalence of CHD (118, 194). The 
results of these studies helped support the American Heart Association’s re-classification of 
physical inactivity from a secondary to a primary risk factor for CHD in 1992 (12). Leisure-time 
physical activity (LTPA), as well as changes in LTPA, has also been shown to be independently 
related to the risk of all-cause mortality and myocardial re-infarctions for individuals with known 
CHD (71, 89, 154, 188). 
     The exact physiological mechanisms by which increased physical activity levels mediate 
CHD risk are unknown. Higher physical activity levels are associated with the effective 
management of the modifiable risk factors while improving cardiorespiratory fitness (CRF), an 
independent predictor of all-cause and cardiovascular mortality (25, 60). Specifically, individuals 
who are more active demonstrate better lipoprotein profiles, lower blood pressure, blood sugar 
and body weights and are less likely to smoke than their sedentary counterparts (60). Thus, 
effective physical activity interventions for individuals with established CHD should enhance 
their risk factor management and minimize the occurrence of recurrent coronary events. 
     Individuals who have had a recent MI or index cardiac surgery (e.g., coronary artery bypass 
graft, percutaneous transluminal coronary angioplasty or valve replacement) are eligible to 
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participate in a cardiac rehabilitation program (CRP). A traditional CRP involves a supervised 
exercise program three times a week for 45-60 minutes (10). The American Association of 
Cardiovascular and Pulmonary Rehabilitation (AACVPR), American College of Cardiology 
(ACC), American Heart Association (AHA) and the American College of Sports Medicine 
(ACSM) recommend that patients with CHD perform a minimum of 30 to 60 minutes of 
moderate intensity activity at least 5 times/week, coupled with an increase in daily lifestyle 
activities (11, 16, 71, 153). These recommendations are based on the dose-response relationship 
between overall activity levels and CHD (11, 12, 90, 188). 
     A typical CRP exercise session lasts 45-60 minutes and usually involves a series of 5-15 
minute exercise bouts on various exercise machines (e.g., treadmill, cycle ergometer, NuStep©, 
etc.) as well as strength training. Research indicates that approximately 75% of phase II CRP 
participants do not perform an adequate amount of physical activity on the days they attend a 
CRP, when caloric expenditure is used to measure physical activity (136, 139). Furthermore, 
individuals enrolled in a phase II CRP are sedentary on the days they do not attend the program 
(133, 138). These facts may be attributable to the average age (e.g., > 55 years) of participants in 
phase II CRPs, the likelihood that they have multiple risk factors, as well the low maximal CRF 
exhibited in men and women (5 and 4 METS, respectively) in this population (5, 15, 138).  Each 
of these variables has been associated with low leisure-time activity levels (55, 138, 177).  
     Another indication that the typical phase II CRP participant is likely not exercising on the 
days they do not attend the program is provided by Meijer et al. (102). These researchers 
examined older adults (e.g., 57 years) whose exercise program mirrored the one commonly 
employed in phase II CRPs (e.g., 2 exercise sessions a week for 12 weeks). Using an 
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accelerometer, the authors reported that subjects demonstrated significantly higher levels of 
physical activity on exercise training days, but their overall activity level did not change. In 
essence, the subjects compensated for their structured exercise activity by decreasing their 
activity on non-exercise training days (102). These results underline the necessity to determine 
effective strategies to enhance the physical activity levels of individuals enrolled in phase II 
CRP, especially on non-CRP days, so that they may enjoy more exercise-related positive health 
outcomes. 
     Exercise prescriptions commonly specify four variables: frequency, intensity, duration and 
type (12). Given that most individuals entering a phase II CRP are older with a remarkably low 
CRF, low and moderate intensity exercise bouts for short durations are recommended at the 
beginning of the program (10, 16, 153). The AHA standards for exercise training of CRP patients 
state that the overall daily activity, including the performance of regular moderate intensity 
exercise, is more important for health than the performance of high intensity exercise. The 
authors cited that although regular high intensity may provide greater benefits, this intensity is 
also associated with less compliance as well as more adverse cardiac events and orthopedic 
injuries (153). Therefore, it is imperative to find practical and effective strategies to increase the 
total volume of low and moderate intensity leisure time physical activities performed by phase II 
CRP participants. 
     Several methods have been utilized to assess physical activity including questionnaires, heart 
rate monitors, doubly labeled water, and motion sensors (e.g., accelerometers and pedometers). 
Each of these activity assessment tools entails benefits as well as limitations (172). Pedometers 
may be the most effective of these given they provide a relatively inexpensive, objective, reliable 
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and valid manner in which to measure ambulation, the most frequently performed activity of 
adults, including seniors (19, 125, 180). In addition, pedometers appear to motivate sedentary 
individuals to increase their physical activity levels by providing immediate feedback and by 
serving as an environmental cue (175). Pedometers are often used in conjunction with 
individualized steps goals and exercise diaries, which increases their effectiveness (39, 175). A 
recent meta-analysis of subjects in 26 pedometer-based interventions demonstrated that they 
significantly increased daily step counts in sedentary adults by 2,491 (a 26.9% increase) over 
baseline (30).  
     There is scientific consensus that individuals with established CHD should accumulate 30 
minutes of moderate intensity at least five days a week (16, 71, 153). Yet it appears that the 
exercise monitoring and counseling strategies currently employed in phase II CRPs results in the 
vast majority of its participants not attaining these activity levels. Thus, it is necessary to 
determine if pedometers can serve as an effective tool to increase the daily activity levels in this 
population.  
Statement of problem 
     The AACVPR, AHA, ACA and ACSM recommend that a minimum of 30 to 60 minutes of 
moderate intensity physical activity be performed on most, preferably all, days of the week for 
individuals with CHD. Individuals who only exercise during phase II CRP (e.g., 30-45 minutes, 
3 days/week) cannot meet these activity goals and thus must exercise on their own as well. The 
recommended core components of CRPs include optimizing primary risk factor reduction, 
coupled with the adoption and maintenance of regular physical activity. Yet CRPs do not provide 
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sufficient counseling or monitoring strategies to ensure its participants are accumulating 
adequate physical activity.  
  
Statement of purpose 
 
     The purpose of this study is to determine whether providing a pedometer and exercise diary to 
phase II CRP patients along with individualized step goals on non-CRP days results in an 
increase in physical activity compared to those receiving typical treatment. The use of 
pedometers in this study will also provide evidence concerning the daily activity patterns of 
phase II CRP participants.  
Significance of the study 
     To date, the overall physical activity patterns of individuals with CHD have not been well 
established. The study will help to establish the baseline step count values for individuals who 
initially enroll in a phase II CRP. The results will determine whether the use of a pedometer and 
step counts goals leads to significant changes in their leisure-time activity levels on the days they 
do not participate in a phase II CRP (e.g., non-CRP days). The Omron HJ 720 ITC pedometer 
can delineate whether changes in leisure time physical activity are accomplished through either 
fragmented bouts (e.g., increased activities of daily life) or continuous activity (e.g., structured 
exercise). This information can be used by allied health professionals who work in phase II CRPs 
to provide practical, specific step count recommendations to help ensure their participants are 
attaining their recommended physical activity levels. 
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CHAPTER II: REVIEW OF THE LITERATURE 
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CHD prevalence and its attendant healthcare costs  
 
     In 2009, the AHA reported that coronary heart disease (CHD) affected over 16 million adults 
in the United States and contributed to over 600,000 fatalities. CHD is the single leading cause of 
death for adults and is also a major cause of physical disability, especially in the ever-increasing 
senior population. More than 1.2 million acute myocardial infarctions (MI) occur annually and it 
is estimated that 15 years of life are lost due to the typical MI. Depending on their gender and 
clinical outcome, people who survive the acute stage of a heart attack have a chance of illness 
and death that is 2.5 to 15 times higher than that of the general population and two-thirds never 
make a complete recovery. Almost 40% of people who experience a MI in a given year will die 
from it. In 2008, the estimated combined direct and indirect cost of CHD was $156.4 billion 
(132). These statistics highlight the necessity of developing cardiac rehabilitation programs 
(CRPs) that minimize the chance of recurrent coronary events in patients with CHD by 
effectively managing their primary risk factors while improving their cardiorespiratory fitness 
(CRF). CRF has been shown to be an independent predictor of all-cause and cardiovascular 
mortality (25, 85). 
Cardiac rehabilitation: overview 
     CRPs have historically included four components. The initial phase consists of hospital-based 
in-patient education and daily ambulation following an index CHD event (e.g., MI) or surgery 
(e.g., coronary artery bypass graft (CABG)). Phase II CR includes 4-12 weeks of 
electrocardiograph (ECG) monitored exercise three times a week for 45-60 minute in an out-
patient hospital setting or wellness program (10). Phase II CR typically begins within 3-6 months 
after an index CHD event or surgery. During this time, participants’ exercise regimens are 
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continually progressed to increase their functional capacity (e.g., VO2max). Common aerobic 
exercise modalities utilized in this program include treadmills as well as arm, cycle, rowing and 
seated stepper ergometers (10). After 4-6 weeks of regular exercise participation, participants 
may pursue a strength training regimen as well. Phase III CR is considered a maintenance 
program without ECG monitoring, but includes clinical supervision in which individuals exercise 
independently. Phase IV provides no ECG monitoring, but entails supervision by health 
professionals (70, 163). Third party insurance providers cover the first and second phases of the 
CRP process, while the later two are self-pay. Individuals eligible for a CRP include those 
diagnosed with CHD and who have had either a myocardial infarction (MI), coronary artery 
bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA), or angina. Based 
on their insurance provider coverage, some individuals with advanced congestive heart failure 
may also participate (157, 163). 
     One of the core components of CRPs is to provide a monitored and structured exercise 
environment, combined with education sessions that teach participants how to effectively self-
manage their primary risk factors for CHD, which reduce disability and promote long-term 
adherence to healthy behaviors (3, 16, 135, 152). Phase II lasts 4-12 weeks based on the 
participants’ insurance provider(s) and their CRF. Individuals with higher CRF capacities may 
only complete 4-6 weeks of CR. Participants typically attend an exercise class for 30-60 minutes, 
three times a week and perform a combination of aerobic and strength training activities during 
which they are continuously ECG monitored. Each week, the duration and/or the intensity of the 
aerobic sessions are increased in order to increase the individual’s endurance and cardio-
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respiratory capacity. In addition, participants attend a 30 minute educational session led by 
various healthcare professionals once a week (3, 163).  
CRPs as effective secondary prevention programs: current challenges  
     Several meta-analyses examining randomized clinical trials have concluded that individuals 
who participate in CRPs show improvement in their primary risk factors (e.g., enhanced CRF, 
lower systolic blood pressure, and better lipoprotein profiles) (35, 113, 160). These primary risk 
factors are closely linked to subsequent lower cardiac and all-cause mortality rates (3, 57, 59, 
163). Ford et al. (57) reported that half of the decline in the U.S. death rates from CHD during 
the last 20 years is attributable to better primary risk factor management. Total physical 
activities, as well as leisure time physical activity, is inversely related to cardiovascular risk 
factors in men and women (63). 
     Individuals with established CHD who complete a phase II CRP have a 20-25% decrease in 
cardiac and all-cause mortality rate, but they do not have reduced non-fatal recurrent MIs (35, 
160). Interestingly, some clinical trials report that CR participants’ exhibit modest or no 
improvement in primary risk factors, specifically weight loss and blood glucose management 
(31, 41, 135). This outcome has been attributed to the low mean caloric expenditure (e.g., 
approximately 270 calories per exercise session) observed during CR participation (139).  
     The role of phase II CRPs in secondary prevention of CHD continues to increase (3, 163). 
Fatalities from acute MI have continued to decline, increasing the number of individuals eligible 
for CRP (162). Hospital stays after MI, CABG and PTCA procedures have declined, which 
reduces the opportunity for in-hospital risk factor interventions (190). Although the number of 
individuals eligible for phase II CRPs has increased, referral rates and enrollment have remained 
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remarkably low. In 2001, approximately 10-20% of the two million individuals eligible for CRP 
participated in the program, a participation rate that has not changed appreciably in the last 
twenty years (41, 92). Contributors to the low CR participation rate include: low patient referral 
rates, inadequate third party reimbursement, poor patient motivation and excessive driving time 
to program sites (92).  
     In 2007, the American Association of Cardiovascular and Pulmonary Rehabilitation 
(AACVPR), American College of Cardiology (ACC) and American Heart Association (AHA) 
published position stands outlining the performance measures for CRPs regarding referral and 
delivery of phase II CRP secondary prevention services. The focus of these position stands is 
based on research indicating that the provision of early out-patient services is the most well-
established strategy in reducing CHD mortality among CRP participants. These new guidelines 
suggest that all hospitalized patients with a qualifying CHD event should be referred to a phase II 
CRP prior to hospital discharge. In addition, all out-patients with a qualifying diagnosis within 
the past year that have not been enrolled in a phase II CRP by their health care provider should 
be referred as well (163). As progressively more individuals are referred to CRPs, these 
programs will be expected to provide better outcome measures regarding their core components, 
including the promotion and adoption of long-term exercise adherence (16, 152).   
     After individuals enroll in a phase II CRP, attrition rates average 25-50% over the three 
month course of the program (16, 106, 136). Thereafter, patients may participate in phase III CR 
maintenance programs, fitness facilities or home-based programs to continue their exercise 
program (26). Only 30-60% of subjects who complete a phase II CRP are still physically active 3 
to 6 months later (52). And one year after completing phase II CRP, the rate of exercise 
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compliance is less than 40% (3). These poor exercise adherence outcomes contribute to the 
finding that 90% of patients who have a CABG procedure revert to unhealthy lifestyles that 
exacerbate their CHD (62). CHD, like may chronic diseases, is more prevalent among 
individuals of low socioeconomic status and minorities. Both of these populations participate in 
CRP at an even lower rate than the national average. Clinicians must consider how they can 
provide the beneficial aspects of CRPs to indigent and minority populations in a safe and 
affordable manner that is consistent with hospital and wellness center based programs (3). 
     Ades et al. (5) reported that the average VO2peak for 2,896 participants entering a phase II CRP 
was 5.53 and 4.14 METs in men and women, respectively. In contrast, 77 participants who had 
regularly participated in a phase II CRP for 4 years demonstrated a VO2peak of 9.1 + 2.8 METs 
(gender disparities not reported) (13). These results underline the importance of identifying 
effective exercise monitoring and counseling strategies so that phase II CRP participants will 
adopt and maintain exercise patterns that improves their functional capacity (35, 113). 
     In 2007, the AACVPR, ACC and AHA outlined the requisite core components of phase II 
CRPs including: optimizing cardiovascular risk reduction, cultivating long-term adoption of 
healthy lifestyle choices, reduction of disability, and promotion of an active lifestyle. Phase II 
CRPs are encouraged to assess baseline physical activity levels using either a questionnaire or a 
pedometer and its participants are expected to demonstrate increased domestic, occupational and 
recreational activity levels (16). Given that questionnaires are subject to recall error and have 
been shown to provide invalid measurements of time spent in moderate intensity physical 
activities, especially walking, pedometers may offer the most practical and accurate means to 
attain the aforementioned assessment and outcome measurements (7, 20, 148).    
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     Pedometers offer an objective, accurate, valid and reliable method to measure ambulatory 
activity with minimal participant burden (19, 142, 171). These inexpensive devices permit self-
monitoring and instant feedback on ambulatory activity. Pedometers may improve self-efficacy 
and motivate individuals to increase their activity levels with minimal counseling (9, 30, 34, 77). 
Given that walking is the most prevalent form of leisure time physical activity for seniors (e.g., > 
65 years), who comprise a large portion of CRP participants, pedometers provide an accurate 
indication of their overall activity levels (14). 
     The Omron HJ-720 ITC pedometer has the ability to provide time and day-stamped, hour-by-
hour step-count data (delineated between aerobic and non-aerobic steps) which permits 
researchers the ability to discern whether subjects are accumulating steps through fragmented or 
continuous physical activity (115). 
     Pedometers may be part of the solution to increase the number of individuals with CHD who 
meet clinical exercise guidelines and would likely exhibit improved CRF levels and risk factor 
management. The use of pedometers and step-count goals can complement traditional CRP 
counseling to provide a novel strategy for self-monitoring of activity levels. These devices have 
been proven to enhance patient motivation and adherence to physical activity goals, which would 
allow participants with CHD to realize the sustained benefits of regular exercise (172). 
AACVPR, AHA, ACC and ACSM physical activity recommendations for individuals with 
CHD 
 
     The AACVPR, AHA, ACC and the American College of Sports Medicine (ACSM) each 
recognize that the promotion and adoption of regular physical activity is imperative for long-
term effective primary risk factor management. Their physical activity recommendations for 
 14 
participants in phase II CRPs is to accumulate 30-60 minutes of moderate intensity physical 
activity > 5 days/week. Activities that entail low orthopedic demands (e.g., walking) should be 
pursued and the activity goal may be accomplished through additional structured activities (e.g., 
10 minutes walking bouts) or increased activities of daily life (ADLS; e.g., gardening, household 
work). Furthermore, the volume of activity of should be gradually increased over time (16, 152).  
     The physical activity recommendations for individuals with CHD regarding the frequency, 
intensity and duration of activity to be performed are similar for each organization. Each concur 
that the physical activity can be intermittent (e.g., a minimum of 10 consecutive minutes) or 
continuous in nature. This recommendation is supported by research findings that suggest that 
three short bouts (e.g., 10 minutes) of brisk walking accumulated throughout the day effectively 
reduces primary risk factors as well as one continuous exercise bout of equal duration (110, 111) 
Furthermore, these recommendations are not appreciably different from those advocated by the 
ACSM for healthy adults (71). Each organization also states that novel approaches which 
effectively deliver CR services and promote adherence to its core components should be 
addressed in future research (16, 152).  
     Minimal adherence to the physical activity guidelines for individuals with CHD would yield 
an energy expenditure of about 1,000 calories/week, which has been associated with a significant 
20-30% reduction in risk of all-cause mortality in the general population (90). Yet individuals 
with established CHD who perform this amount of physical activity have been documented, via 
arteriograms, to experience progression of the coronary artery lesions, whereas a total weekly 
volume of physical activity equal to 1,500-2,100 kcal is associated with coronary artery disease 
stability and/or regression (67, 69, 112). Thus, some researchers have concluded that phase II 
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CRP participants must pursue physical activity outside of their supervised exercise sessions in 
order to maximize their CHD management (13). 
Research supporting the exercise recommendations for individuals with CHD 
     The aforementioned activity guidelines for individuals with CHD are based upon 
epidemiological and clinical research demonstrating a positive dose-response relationship 
between physical activity and reductions in cardiac and all-cause mortality (90, 118). For 
instance, Paffenbarger et al. (118) demonstrated that versus the least active group of subjects, 
individuals who expended 71-143 kcal/day had a 22% reduction in all-cause mortality compared 
to their inactive peers. Individuals who expended 143-214 kcal/day demonstrated a 27% 
reduction in all-cause mortality; mortality rates continued to decrease up to a caloric expenditure 
of 300 kcal/day.  
     Recently, researchers have examined whether the dose-response relationship is consistent in 
elderly individuals with CHD, who constitute the majority of CRP participants (90). Using 
sedentary subjects as the referent group, the risk of mortality was reduced in a curvilinear fashion 
with each 550 kcal/week increase in activity up to 4,000 kcal/week. The intensity of physical 
activity had no effect on mortality risk after consideration of weekly EE. Interestingly, the 
authors also noted that a caloric expenditure of 1,500 kcal/week represented the point at which 
relative risk was reduced by approximately 50% of the maximal reduction (e.g., 4,000 kcal). 
These results were independent of sex, age, smoking, adiposity, number of co-morbid conditions 
and type of CHD (81).    
     Numerous studies have reported that participants in phase II CRPs improve their 
cardiorespiratory fitness (CRF) approximately 20% (1, 27, 31). This outcome is important since 
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an inverse dose-response relationship has been documented between CRF and mortality for 
individuals diagnosed with CHD (88, 97, 187). This relationship also holds true for individuals 
with CHD who pursue contemporary preventive treatments such as statins or primary PTCA. 
Specifically, Keteyian et al. (85) reported that in 2,812 patients with CHD every 1 ml/kg . min−1 
increase in peak VO2 is associated with a 15% decrease in all-cause mortality (85). Additional 
research demonstrates that the magnitude of exercise training induced increases in CRF has been 
shown to independently predict a decrease in cardiovascular mortality for individuals with CHD 
(185).  
     CRF has also been identified as an independent predictor of recurrent cardiac episodes and 
duration of re-hospitalizations for individuals with established CHD (192). Kavanaugh et al. (84) 
examined over 12,000 men who had either had an MI or CABG procedure for an average of 8 
years. VO2peak levels of < 15, 15 to 22 and > 22 ml/kg . min-1 produced adjusted hazard ratios of 
1.00, 0.62 and 0.39 for cardiac mortality and 1.00, 0.66, and 0.45 for all-cause mortality. 
Additional research indicates that a high exercise capacity (> 10 METs) is associated with 
excellent prognosis even for individuals with three-vessel CHD (92). In a population of 5,000 
individuals with CHD, each 3.5 ml/kg . min-1 increase in CRF decreased all-cause mortality by 
17%. Thus, as in the general population, low CRF is a predictor of higher all-cause mortality in 
individuals with CHD (25).  
     Several clinical studies have used quantitative angiographic measures to determine the effect 
of regular PA on coronary lesions. Niebauer et al. (112) has suggested that LTPA independently 
contributes to enhanced primary risk factor management and prevents the progression of 
coronary lesions. The authors examined variables that contribute to the progression of CHD in 
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113 men over a six year period. The intervention group was asked to exercise for 30 minutes 
each day and attend two 60 minute group exercise training sessions, both at an exercise intensity 
of 75% HRmax each week. There was only a 33% compliance rate to the group sessions over 6 
years. During the first year of study, individuals expending 1,500 kcal/week demonstrated no 
changes in coronary stenoses while patients who accumulated 2,200 kcal/wk experienced lesion 
regression. Subsequently, during the six-year follow-up period, regression of CHD lesions 
occurred in subjects who expended an average of 1,785 kcal/week in LTPA. Multivariate 
regression analysis identified only CRF as independently contributing to angiographic changes 
(111). This result coincides with Schuler et al. (146, 147) who noted that coronary lesion 
regression was only related to improvements in CRF (23% increase) in a group of 18 men who 
performed three hours of moderate intensity exercise per week for one year. These authors also 
noted that improvement of myocardial perfusion may be achieved independently from regression 
of coronary lesions.  
     Hambrecht et al. (67) attempted to identify the effect of different levels of LTPA on CRF and 
progression of coronary atherosclerotic lesions for 62 individuals with CHD. Subjects were 
prospectively randomized either to an intervention group participating in regular physical 
exercise on their own or to a control group receiving usual care. After one year, an analysis of all 
participants revealed the lowest level of LTPA associated with CHD progression was 1,022 + 
142 kcal/week as opposed to patients who experienced no change (1,533 + 122 kcal/week) or 
regression in their coronary lesions (2,204 + 237 kcal/week). Interestingly, subjects had to 
expend approximately 1,400 kcal/week during LTPA to significantly improve their CRF (67). 
This amount of activity appears to have no effect on coronary lesions for individuals with 
 18 
established CHD, yet is associated with a decrease in cardiac and all-cause mortality (81, 90, 
118).  
     Additional evidence indicates that exercise training may be superior to angioplasty. 
Hambrecht et al. (69) observed the angiographic changes over 12 months in 94 men with 
established CHD and stable angina who were randomized to exercise training or angioplasty with 
stent placement. Exercise training consisted of 10-minute cycle ergometry sessions 6 times daily 
at 70% HRmax for 2 weeks, followed by a year of unsupervised 20 minute daily home exercise 
sessions plus a weekly supervised 60-minute session. At 12 months, VO2max increased 
significantly (16%) in the exercise group with no change (2%) in the group receiving 
angioplasty. The target lesion did not change in the exercise group, while 15% of the angioplasty 
subjects developed re-stenosis (e.g., a luminal narrowing of > 50%). Overall CHD progression 
was only significantly reduced in the exercise-trained group. Six patients in the exercise training 
group and 15 patients in the angioplasty group experienced a major cardiovascular event, 
including nonfatal MI, stroke, a revascularization procedure, or hospitalization for angina, giving 
a significantly higher event-free survival in the exercise subjects (88% versus 70%) (69). 
     Ornish et al. (116, 117) used angiographic documentation to show that 28 individuals with 
CHD who adopted and sustained extensive lifestyle changes had a significant reduction in 
coronary lesions at one and five years. It is difficult to determine the extent that regular physical 
activity contributed to these results due to dietary intervention employed in the study. 
Participants averaged 35 minutes of moderate intensity activity each day. They also reduced their 
dietary fat intake to 14 grams/day and cholesterol intake to 12 mg/day, which likely made a 
considerable contribution to lesion regression (116, 117).  
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     The results from Hambrecht et al. (67) and Niebauer et al. (112) suggest that high volumes of 
physical activity, completed at moderate to high intensities, corresponding to approximately 
1,500 and 2,200 kcal/week are associated with no change and regression of coronary lesions, 
respectively. Therefore, it appears that a significant amount of moderate and high intensity 
physical activity is required to effective manage coronary lesions. 
     In order to attain the energy expenditure levels associated with management and regression of 
coronary lesions, an individual who weighs 85 kg would have to walk at a pace of 3 mph for 
approximately 5 hours per week or accumulate 15 miles to expend 1,500 calories, and 
accumulate approximately 22.5 miles (e.g., walking for 7.5 hours) to attain a 2,200 caloric 
expenditure, respectively. This estimation is supported by research which utilized a questionnaire 
to assess the relationship between the effects of LTPA on mortality rates in 5,934 older men (63 
years) with established CHD. Over a 5 year period, individuals who performed regular walking 
40 or more minutes/day exhibited a significant reduction in cardiac (RR = 0.39) and all-cause 
mortality (RR = 0.48) even after adjustment for age, smoking, obesity, stroke, diabetes and 
history of MI.  Individuals who participated in physical activity at light, moderate or 
moderate/vigorous levels demonstrated a RR of 0.42, 0.47 and 0.63 for all-cause mortality versus 
their sedentary counterparts. A similar relationship was evident for cardiovascular mortality 
(188). 
     Previous research indicates these calorie goals cannot be feasibly attained through exercise in 
phase II or III CRPs alone, given the typical caloric expenditure (e.g., 270-300 kcal) documented 
during these exercise sessions (137, 139). Therefore, a significant amount of additional moderate 
intensity LTPA would have to be pursued as a complement to regular phase II CRP exercise 
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session participation in order to attain the activity level that maximizes the benefits of regular 
physical activity regarding the maintenance or minimal regression of pre-existing coronary artery 
lesions. 
Energy expenditure during phase II and III CRP participation  
     CRP programs are designed to increase physical activity levels of its patients so that they can 
increase their functional capacity to more readily perform the activities of daily life and 
effectively manage their primary risk factors. The present research indicates the majority of 
participants in CRPs do not meet the activity recommendations for individuals with CHD.  
     Savage et al. (136) examined 120 phase II CRP participants (63 years, BMI of 29 kg/m2) who 
expended about 270 kcal per exercise session during a 12 week period. Participants exercised 
three times a week for 45 minutes at 70-85% HRmax. Using open-circuit spirometry, men and 
women less than 65 years expended significantly more (men; 323 kcal versus 266 kcal, women; 
230 kcal versus 171 kcal) calories per session than individuals older than 65. Subjects did not 
favorably improve body weight, cholesterol and other risk factors for CHD. Overall, 73% of 
participants did not achieve a 1,000 calorie weekly energy expenditure, which is the minimum 
volume of activity suggested for this population.  
     Scharier et al. (139) measured the caloric expenditure by open circuit spirometry in 30 phase 
III CRP participants (64 years, BMI of 28.8 kg/m2). The average caloric expenditure of 
participants who had been enrolled in phase III CRP for 19 months was 250 calories/session. 
Participants exercised three times a week for an average of 47 minutes at 60-80% HRmax. 
Surprisingly, 83% of patients did not expend 300 kcal/session and 40% did not even expend 200 
kcal/session. A 300 calorie energy expenditure (EE) is considered necessary to attain significant 
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improvements in cardiovascular health (31). The results of the two prior studies are limited by 
the fact that exercise was not quantified outside of CRP participation and patients may have 
fulfilled their weekly exercise requirement with home-based physical activity (135).  
     In another study of 77 phase III CR participants (68 years, BMI of 27.0 kg/m2), an 
accelerometer was used to document their total weekly amount of activity as well as the amount 
of physical activity performed on days individuals attended the CRP versus days they did not. 
Overall EE averaged 1,597 + 846 kcal/week with subjects spending approximately 376 and 125 
minutes in light and moderate intensity activity, respectively. Vigorous activity participation was 
negligible. Activity levels were significantly higher on CRP days than on non-CRP days; 299 + 
161 versus 177 + 113 kcal/day, respectively. Subjects also spent significantly more time in low 
and moderate intensity activities on CRP versus non-CRP days (low intensity; 59.7 + 19.8 versus 
49.3 + 19.3 minutes, moderate activity; 26.4 + 20.4 versus 10.5 + 14.6 minutes) (13). 
     These results concur with prior research that neither phase II nor III CRP participants perform 
an adequate volume of exercise during structured exercise alone to achieve the suggested activity 
levels for individuals with CHD. Furthermore, their overall volume of activity is insufficient to 
maximize the possibility of coronary artery lesion stability or regression. These results indicate 
that the amount of physical activity was generally adequate on CRP days, but failed to reach 
target levels on non-CRP days. Thus, CRP participants should be encouraged to incorporate 
lifestyle physical activity, additional exercise, or both on non-CRP days to supplement their 
structured activity and attain the recommended activity levels. Regarding exercise modality and 
intensity recommendations for this population, it is important to note that subjects in Scharier et 
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al. study (139) self-selected low and moderate intensity activities (predominantly walking) and 
that they may consider vigorous exercise too demanding.  
Effectiveness of phase II CRPs in mitigating cardiac and all-cause mortality 
     National and international clinical guidelines indicate that exercise therapy is of central 
importance to phase II CRPs (135) since physical inactivity has been identified as a primary risk 
factor for CHD (3). The relative risk of CHD associated with physical inactivity ranges from 
1.5–2.4, an increase in risk comparable to that observed for high blood cholesterol, hypertension 
or cigarette smoking (160). A substantial body of evidence indicates that phase II CRP 
participants experience a significant decrease in all-cause and cardiac mortality (approximately 
20-30% for both) versus individuals who receive usual care after an index cardiac event (35, 70, 
113, 160). Today, an array of new drug therapies coupled with efficacious less invasive surgical 
procedures are employed in the routine management of cardiac patients. Yet contemporary meta-
analyses report the benefits of phase II CRPs regarding all-cause and cardiac mortality are 
similar for recent as well as older clinical trials (161, 166).  
     Taylor et al. (161) conducted a recent meta-analysis of risk factor outcomes for CHD patients 
enrolled in a phase II CRP. Forty-eight clinical trials were reviewed which included 8,940 
patients randomly assigned to exercise-based cardiac rehabilitation or usual care. The study 
population was required to have a follow-up of at least 6 months (up to 69 months) in a 
supervised or unsupervised exercise programs. Subjects averaged 2.7 exercise sessions of 53 
minutes per week and exercised at 76% VO2max. In agreement with prior meta-analyses of similar 
populations, total mortality and cardiac mortality were decreased by 20% and 26%, respectively, 
in phase II CRP participants versus individuals with CHD who received usual care (114). CRF 
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levels increased 20% and participants demonstrated a significant reduction in total cholesterol (-
14.3 mg/dL), triglycerides (-20.4 mg/dL) and systolic blood pressure (-4.2 mmHg) and a lower 
proportion of patients reported smoking versus usual care. In contrast, there was no significant 
difference between the groups regarding low density lipoprotein (LDL), high density lipoprotein 
(HDL), or diastolic blood pressure (161). Although anthropometric results were not reported, 
most research indicates participants in traditional phase II CRPs do not lose weight which is 
likely due to the low average number of calories expended per session and the short duration of 
CRPs (3, 31 135). The authors concluded that the improved mortality outcomes may be 
attributable to the improvements in CRF levels, primary risk factor management, reduced 
ventricular fibrillation, or improved MI survival secondary to exercise-induced ischemic 
preconditioning (161). 
     Recent clinical trials have reported that participation in phase II CRPs yields favorable effects 
as well for non-traditional risk factors implicated in the progression of CHD. Significant 
improvements in endothelial function, C reactive protein, fibrinolysis, left ventricle function, 
autonomic tone and heart rate variability have each been noted (3, 23, 54, 68, 92). The 
significant improvement in endothelial function with CRP participation may be the most 
important of these variables since it is an independent predictor of cardiac events (47, 54). 
     Higher volume exercise programs have proven to be more efficacious regarding primary risk 
factors for CRP participants. Using primarily walking as the exercise modality, Savage et al. 
(137) supervised 15 subjects (62.5 years, BMI of 31.1 kg/m2) who walked 60-90 minutes 5-7 
days/week at 50-60% VO2peak for four months within a CRP. Subjects were counseled to expend 
> 1,500 kcal/week, an activity level associated with mitigating coronary artery lesion progression 
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and substantially higher than the caloric expenditures reported in traditional phase II CRPs (14, 
111, 135). Subjects exhibited a body weight loss of 4.6 kg and a fat loss of 3.6 kg while 
maintaining fat free mass. Furthermore, triglycerides (-20.4 mg/dL; 23.7% reduction), TC/HDL-
C ratio (-1.2; 14.5% reduction) and fasting insulin (-2.9; 22.3% reduction) also decreased 
significantly, while VO2peak increased by 21.2%. In agreement with the meta-analysis of phase II 
CRPs conducted by Taylor et al. (161), there was no significant changes in LDL (-8.7 mg/dL) or 
HDL (2.3 mg/dL) levels. Subjects wore a Caltrac accelerometer for 7 days to estimate activity-
related energy expenditure (AREE) at the 2nd and 16th week of the intervention. AREE 
increased 71% from 2,726 ± 1,089 kcal/day to 4,673 ± 1,703 kcal/day and there was a significant 
relationship between AREE and fat loss (r = 0.69). No adverse cardiac events were reported 
during the study. 
     These results indicate that participation in traditional CRPs leads to moderate improvements 
in modifiable primary risk factors while significantly reducing cardiac and all-cause mortality (3, 
15, 35, 59). Phase II CRPs can enhance their ability to monitor and improve the daily physical 
activity patterns of their participants using pedometers. Therefore, participants may be able to 
increase their weekly energy expenditure to a level that is associated with more pronounced 
favorable changes in primary risk factors.    
Phase II CRPs: structured versus unstructured programs 
     Home-based exercise programs using occasional contact by healthcare professionals have 
been proven to be as effective as center-based programs regarding non-fatal MI re-infarctions, 
CRF improvement as well as cardiac and all-cause mortality outcomes (26, 32, 63). Gordon et al. 
(63) compared the results of 142 patients (75% men, 61 years, BMI of 29.8 kg/m2) who were 
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enrolled for 12 weeks in (1) a traditional phase II CRP, (2) a physician-supervised nurse case 
management program or (3) a community-based exercise program monitored by exercise 
physiologists. All participants were given a report outlining their current CHD risk factors, the 
goal level for each risk factor and an individualized action plan for achieving these goals. Home-
based patients were encouraged to perform 30-60 minutes of aerobic exercise at 60-85% peak 
HR and/or at a RPE of 11-13 at least 3 days per week for 12 weeks. All three interventions 
significantly improved CRF, systolic and diastolic blood pressure, total cholesterol, and low 
density lipoproteins with no statistical differences between the three groups (63). 
     Recent technological advancements have allowed healthcare professionals to effectively 
monitor individuals’ exercise progress and provide appropriate feedback while they are at home. 
Southard et al. (155) utilized an Internet-based program that permits nurse case managers to 
provide risk factor management training, risk factor education and monitoring services to 
patients with CHD. The Internet program entailed electronic discussion groups, online 
assessments and interactive education modules and separate interfaces for other health care 
providers. Patients were required to log in once a week for 30 minutes, communicate with their 
case manager via e-mail, complete assigned education modules and report their daily blood 
pressure and minutes of exercise. Compared to usual care subjects over a six-month period, 
participants in the Internet based intervention had less cardiovascular events (3.1% versus 
15.7%) and enjoyed more weight loss (-3.68 versus 0.48 pounds). There was no significant 
difference between the two groups regarding blood pressure, lipid levels, depression scores, 
minutes of exercise or dietary habits. The authors noted that the program could be more effective 
with the integration of Internet-enabled devices for monitoring progress in clinical measurements 
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such as blood pressure, blood glucose, weight and exercise (e.g., pedometers) that could send 
information to case managers and physicians in real time (155). 
     The promise of using pedometers to measure the amount of activity associated with positive 
health outcomes for home-based CRPs is supported by preliminary results from Houle et al. (76). 
In this study, a clinical nurse specialist (CNS) contacted CRP-eligible participants intermittently 
who were given a pedometer and exercise log upon hospital discharge. The CNS provided them 
with individualized exercise goals based upon their reported activity patterns (e.g., step count 
results). The control group received typical care and wore a blinded pedometer. At 6 months, the 
experimental subjects averaged 2,400 steps/day more than the controls while demonstrating 
significantly lower LDL levels, systolic blood pressure, and waist circumference versus controls 
(76).   
     Part of the reason home-based exercise programs have documented success commensurate 
with hospital-based programs may be due to the efficacy of walking in eliciting health outcomes. 
Brisk walking, the most commonly performed exercise in the aforementioned studies, has been 
demonstrated to confer favorable outcomes in regards to cardiac and all-cause mortality in 
middle aged and elderly men and women (96, 97, 160). It is also important to note these results 
are attained without additional risk of adverse cardiovascular events and can be easily 
implemented for individuals who do not have the financial resources, time or logistical ability to 
participate in a traditional center-based phase II CRPs. These findings support the use of 
pedometers to complement center-based phase II CR exercise sessions in order to improve 
activity levels on non-CRP day levels, which can increase the number of individuals attaining the 
activity goals for individuals with CHD during CRP participation. By doing so, the health 
 27 
outcomes of phase II CR participants will be enhanced in a practical, cost effective manner that 
can readily complement the current CRP model. 
Measuring habitual physical activity: pedometers versus physical activity questionnaires 
     Phase II CRPs are encouraged to assess baseline physical activity levels using either a 
questionnaire or a pedometer (16). Although physical activity questionnaires (PAQs) have been 
used for decades to quantify activity levels, they have several shortcomings which limit their 
reliability and validity. Individuals commonly misrepresent the total volume of daily physical 
activity level they perform due to misclassification of the frequency, intensity and/or duration of 
physical activities (7, 105, 148). In addition, many researchers use metabolic standards that 
overestimate the energy expenditure for certain activities and populations (especially middle 
aged and senior populations) (7, 18, 105). These limitations may lead to errors in physical 
activity estimation. There is also a lack of standardization for PAQs regarding the syntax 
utilized, methods of analysis and subsequent interpretation (148). 
     Pedometer measurements of physical activity are only moderately correlated with PAQs (r 
range = 0.33-0.48) (20, 148). These disparities have been attributed to study populations that 
were mostly sedentary or whose activities were limited by chronic disease (e.g., chronic 
obstructive peripheral disease, peripheral vascular disease) as well as the shortcomings of PAQs 
previously mentioned (148, 169). 
     Pedometers have several advantages for researchers who wish to assess physical activity. 
First, they can accurately determine an individual’s cumulative daily walking levels and are 
likely to reflect LTPA levels since walking is the most common performed of LTPA performed 
by adult Americans (150). These devices are relatively inexpensive, easy to use, and lightweight 
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(18, 182). Pedometers provide an absolute value (e.g., steps) which can be used to estimate the 
distance an individual walks. Step counts are readily understood by the general population and 
are widely used for prescribing exercise. Step counts can also provide comparisons across 
different studies (142).  
Methodological considerations for using pedometers: step counts and monitoring time 
frame 
 
     Pedometers provide a variable (e.g., steps) which researchers can use to assess physical 
activity patterns and determine their association with various health outcomes in the general and 
special populations (173). These results can be used to provide simple, uniform exercise 
recommendations for the general public. Pedometers are increasingly being used in clinical and 
intervention research trials. In order to facilitate the interpretation and comparison of results from 
these studies, researchers should address a series of methodological considerations. 
     Prior research has demonstrated that pedometer-determined data are highly variable. The 
variability is partially attributable to the day of the week monitored, attendance at work, 
participation in aerobic exercise, sports activities, the weather, season, injury status or sickness 
(17, 148, 171, 180). These factors contribute to the high standard deviation relative to mean daily 
step counts that has been consistently reported in healthy and special populations (9, 103, 142). 
In order to account for these possible variations, researchers have sought to establish the 
requisite number of days that provide a reliable and accurate estimation of an individual’s 
habitual activity patterns.  
     The intra-class correlation (ICC) is a statistical technique that measures the internal 
consistency for a data set. Regarding the assessment of pedometer-based ambulatory activity, the 
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ICC estimates the consistency of step counts collected over multiple days, providing a measure 
of intra-individual variability (38). For instance, if the ICC for a single day of pedometer 
monitored activity in a group of subjects was 0.60, then approximately 60% of the variance in 
their daily ambulatory activity could be accounted for by any single given day of data collection. 
A monitoring time frame which provides an ICC of 0.80 has been noted to accurately reflect an 
individual’s habitual activity patterns, since higher values do not provide significant greater 
explanations of intra-individual variability (17).  
     In order to establish the number of days required to estimate weekly mean pedometer-
determined steps/day in free-living conditions, Tudor-Locke et al. (183) assessed the physical 
activity patterns of 90 subjects (63% females, 49.1 years, BMI of 27.1 kg/m2) for seven 
consecutive days using a pedometer. The criterion was the mean steps/day for the observation 
period and the average steps count for the cohort was 6,838 + 3,643 steps/day. The authors 
concluded that a minimum of three days of monitoring were necessary to obtain an acceptable 
ICC reliability level of at least 0.80 (range 0.86-0.91) to estimate weekly activity levels.  
     Recently, Clemes et al. (38) examined the physical patterns of 212 adults (64% female; 38.3 
yrs; BMI of 27.9 kg/m2) who wore a Yamax SW-200 for 28 consecutive days to determine the 
number of days of monitoring required to estimate monthly activity. The mean step counts 
during the 28 day period served as the criterion. Approximately 76% of the subjects were 
allocated to a reliability group and the remainder served as a confirmation group. The average 
daily step count for the cohort was 9,090 + 2,829. ICCs were computed for the one, two, three 
and four week periods as well as for different combinations of any two, three, four, five, six or 
seven days. The ICC in the reliability group for any single given day was 0.41. All combinations 
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of six days or more had ICCs above 0.80, while a seven day period had an ICC of 0.86. 
Importantly, there was a significant relationship between mean step counts calculated from the 
initial week of monitoring and the criterion (r2 = 0.91, p < 0.001). The authors recommended that 
researchers collect pedometer-based step count data over a 7-day period to accurately and 
reliably estimate monthly activity. This is based on previous studies indicating that step counts 
are consistently significantly lower on Sundays and if one day of data is missed then the resultant 
ICC (e.g., > 0.80) will remain sufficiently high to reliably estimate mean monthly activity.  
     Togo et al. (169) stated that intra-individual variations in physical activity may be of a greater 
magnitude in the elderly population compared to younger adults because their daily schedules 
are not governed by academic requirements or full-time employment. The typical phase II CRP 
participant is typically older (e.g., 57 years) and is likely to no longer work full-time (15). 
Preliminary research assessing factors affecting the baseline activity patterns (e.g., first week of 
enrollment) for phase II CRP participants report an inverse relationship (r2 = 0.09, p < 0.002) for 
the number of days since their index cardiac event, but a positive correlation with their functional 
capacity (e.g., r2 = 0.24, p < 0.0001) (25). Furthermore, this population’s activity levels are lower 
on the days they do not participate in a phase II CRP versus days that they do (13, 14, 26, 138). 
These unique circumstances warrant an initial monitoring time frame of at least 7 days to 
establish an accurate indication of phase II CRP participants’ baseline weekly or monthly 
physical activity levels.  
Pedometer reactivity 
      When assessing physical activity patterns, researchers must attempt to minimize reactivity. 
Reactivity occurs when an individual changes his/her behavior due to awareness that they are 
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being monitored. Given that pedometers provide instant feedback on ambulatory activity, this 
may motivate individuals to increase their activity levels (e.g., pedometer reactivity). If this 
occurs it may increase intra-individual variability, change the baseline physical activity level and 
make it more difficult to detect inter-individual differences over time. Any of these 
developments would compromise the validity of pedometer-assessed activity (36, 37, 169). 
     Several studies have used a randomized controlled crossover study design to determine if 
pedometer reactivity occurs (9, 53, 99). This study design provides increased sensitivity, less 
variability and requires a small sample size. Matevey et al. (99) noted the absence of reactivity 
when examining 28 middle aged adult subjects (57% female, 47 years, BMI of 25.1 kg/m2). Half 
of the subjects wore a sealed pedometer for one week during which their results were monitored 
by a research staff. The following two weeks they did not wear a pedometer (e.g., washout 
period) and then they wore an unsealed pedometer for one week while recording their daily step 
counts. The other participants followed the same protocol in reverse order. Subjects were not 
given instructions regarding their activity levels. The cohort averaged 7,760 + 3,194 steps/day 
during the two weeks of pedometer-assessed activity. Regardless of sealed or unsealed 
assessment, gender or order of pedometer assignment, there were no significant differences in 
mean step counts. Also, steps per day did not significantly increase during the first few days of 
monitoring. Subjects took 419 more steps/day (7,969 versus 7,550) when the pedometer was 
unsealed, a 5.55% relative difference. The ICC for mean steps per day between the two 
pedometer conditions was 0.84, an indication of strong repeatability.  
     Alison (9) examined 103 older subjects (63% women, BMI of 25.4 kg/m2) over a two week 
time period. The participants had higher steps counts on days when they wore an unsealed 
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pedometer and recorded their weekly step counts (e.g., 408 steps/day, p = 0.02). This disparity 
amounted to a 5% relative increase in the participants’ average daily step counts (i.e., 8,400 to 
8,808 steps/day), when wearing an unsealed versus sealed pedometer, similar to the absolute and 
relative differences in step counts observed by Matevey et al. (99). Conversely, there were no 
differences regarding gender or order of pedometer assignment. Thus, the authors concluded that 
although pedometer reactivity may have occurred, the disparity in activity levels attributable to it 
should not be considered clinically significant.  
     Lastly, Marshall (98) attempted to discern if pedometer reactivity occurred in 103 older adults 
(60 years, BMI of 25.5 kg/m2) while wearing a pedometer for two weeks. Half of the subjects 
monitored and recorded their step counts for a week and the following week the pedometer was 
sealed. The remaining subjects completed the protocol in reverse order. Subjects accumulated 
significantly more steps per day (e.g., 400) when monitoring their step counts versus the sealed 
pedometer protocol (8,767 versus 8,360 steps/day). This disparity is 4.9%, which is similar to 
results in previous studies.  
     Presently, several authors have concluded that if pedometer reactivity exists it is minimal, it 
dissipates quickly (e.g., less than three weeks) and it only affects certain types of individuals (9, 
53, 98, 99). 
    Clemes et al. (37) noted that in the above study protocols, the subjects were all aware they 
were wearing pedometers which may engender its own reactivity. In order to control for this 
possible confounding variable, 50 subjects (26 years, BMI of 23 kg/m2) were asked to wear what 
they thought was a sealed body posture monitor for a week. After this time, their results were 
recorded and then they were informed they had been wearing a pedometer and asked to wear it 
 33 
for another week and to record their daily step counts. Mean daily steps counts increased 
significantly (9,541 + 3,186 versus 11,385 + 3,763) for the sealed and unsealed conditions, a 19.3 
% relative difference. Thus, the authors concluded that pedometer reactivity exists and that it has 
implications for short-term studies (e.g., less than a week).  
     Recently, Clemes et al. (39) expanded the aforementioned study protocol. Sixty three subjects 
(23.6 years, BMI of 22.7 kg/m2) wore what they thought was a sealed body posture monitor (e.g. 
covert method) for one week, and subsequently wore the pedometer for another week under the 
following three conditions: blinded, unsealed and unsealed with an activity log for an additional 
week. There was a significant overall effect (p < 0.001) of condition as the covert method results 
were 8,362 + 2,600 steps per day; blinded pedometer 8,832 + 2,845 steps per day; unsealed 
condition 9,176 + 3299 steps per day; unsealed pedometer and diary condition 9,635 + 2,709 
steps per day (a 15.2% relative increase). Post hoc analyses identified that mean step counts were 
significantly higher in the diary condition than those reported during both the covert and sealed 
conditions (both p < 0.003). 
    Given that researchers have stated that up to a 10% level of error is acceptable in free-living 
conditions, the amount of measurement error reported examining the effects of pedometer 
reactivity (excluding Clemes et al. (36, 39) on daily step counts is acceptable and does not 
indicate that pedometer reactivity leads to measurement bias (181). Furthermore, these results 
suggest that if pedometer reactivity does exist, it will be more pronounced in the initial 
monitoring period and will diminish over time. Thus, results of studies assessing pedometer-
based activity over a substantial time duration (e.g., greater than 3 weeks) are unlikely to be 
adversely affected by pedometer reactivity. 
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Validity and reliability of pedometers: an objective measurement of physical activity 
    Pedometers are simple, lightweight devices that measure the number of steps and estimate 
distance walked. In the 1960s, gear-driven mechanical pedometers were used in Japan to monitor 
an individual’s daily physical activity (73). Unfortunately, mechanical pedometers had 
questionable accuracy and reliability at walking speeds of 54-107 m/min (2.0 - 4.0 mph) and thus 
were deemed invalid as research tools (142). In the 1990s, electrical pedometers were developed 
as a more accurate means to measure ambulatory activity. An electronic pedometer has an 
internal horizontal spring-suspended lever arm that moves up and down with normal walking 
movements. With each step, an electrical circuit closes and one event is recorded (18). A 
pedometer cannot accurately measure the intensity of ambulatory movement, nor can it measure 
activities such as recumbent cycling, arm ergometry or resistance exercise. It does provide the 
means to objectively quantify an individual’s amount of daily walking activity, which accounts 
for the majority of calories expended by most adult Americans (150). Significant construct and 
convergent evidence continues to accumulate indicating that pedometers provide a valid measure 
of physical activity.   
     The convergent validity of pedometers indicates the extent to which its ability to quantify 
physical activity, via steps/day, is associated with other means designed to measure physical 
activity. Tudor-Locke et al. (172) reported that pedometers demonstrated a strong correlation 
with a series of accelerometers (r = 0.86), time spent in observed activity (r = 0.82) and observed 
steps during running and walking (r range of 0.80-0.97) at typical ambulatory speeds in the adult 
population. Researchers have noted that pedometers display reduced accuracy during slow 
walking speeds of 54 m/min (e.g. 2 mph) or less. This is due to the fact that the sensitivity 
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threshold of pedometers is designed to identify the vertical accelerations of normal walking. The 
magnitude of vertical acceleration needed to trigger a step is 0.50gs or more, which means that 
shuffling or very slow walking are unlikely to be detected (18). Further, 2 mph is a walking 
speed much slower than the self-selected average walking speed for healthy adults during free-
living activity (174).  
     The “gold standard” for measuring of total energy expenditure (EE) is the doubly labeled 
water technique (DLW) (21, 105). Few research studies have compared the estimated EE 
obtained by pedometers with DLW. One study demonstrated a strong relationship (r = 0.61) 
between the two measurement techniques in subjects with peripheral vascular disease (PVD) 
(175). Another study reported that a foot-ground pedometer was highly correlated to DLW (r = 
0.86) and provided accurate EE estimates up to 3,000 kcal/day in young male and females adults 
confined to a ship (161). In contrast, two studies examining middle aged, overweight and young 
healthy adult women reported that pedometers underestimated physical activity related EE by 
anywhere from 25-46% compared to DLW (93). Additional measures of EE, including heart rate 
(r range 0.46 to 0.88) estimated EE and indirect calorimetry (r = 0.49 to 0.81) have demonstrated 
moderate to strong correlations with pedometers.      
     The construct validity of pedometers can be evaluated by determining if their output 
(steps/day) coincides positively or inversely with other measures of theoretically-related 
parameters (e.g., age, anthropometric measures, fitness, metabolic values) (173). Tudor-Locke et 
al. (173) reported an inverse relationship with age (r = -0.021), BMI (r = -0.027) and overweight 
(r = - 0.22) and pedometer-based physical activity. Depending upon the fitness assessment 
protocol, the association between pedometer-determined physical activity and CRF range from 
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weak to moderate (r range 0.22-0.69) (0). Additional research is warranted regarding the 
examination of the relationship between steps/day and health outcomes (e.g., blood pressure, 
cholesterol, etc.) in special populations. The results of these studies are likely to strengthen the 
construct validity of pedometers. To date, there is sufficient evidence concerning the construct 
and convergent validity of pedometers to warrant their use for research, evaluation and 
intervention purposes.    
The validity and accuracy of the Omron HJ series pedometer 
 
     The Omron HJ-720ITC contains two piezo-electric accelerometers oriented perpendicular to 
each other. Ambulation generates a sinusoidal curve of vertical acceleration versus time and 
whenever the curve crosses the zero line a step is recorded (142). The dual-axis accelerometer 
design permits steps to be counted accurately regardless of its orientation (91, 130). It can be 
worn in several positions (e.g., shirt, belt, pants pocket) (49). This pedometer trait is beneficial 
for researchers and subjects. Subjects cannot be continuously monitored and will spend most of 
their time unsupervised. Thus, daily pedometer placement cannot be monitored by the 
researcher. With the Omron pedometer, individuals can readily place the pedometer in their 
pocket and do not have to be concerned about wearing it on a particular location to ensure its 
accuracy. Participant burden is further minimized by the pedometer’s internal clock which 
reverts to 0 each day at 12:00 a.m. and thus it does not have to be reset. 
     The mechanism and algorithm used to measure overall and aerobic steps in this Omron 
pedometer have been validated and proved to be reliable for younger and older populations, in 
laboratory settings at designated treadmill speeds (2.0-4.0 mph), flat surfaces in free-living 
environments at self-selected speeds (e.g., slow, normal, and fast) (48, 91, 131), and when worn 
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in various positions (49, 131). Also, it has provided valid steps counts for stair climbing at a 
typical pace (e.g., 80 steps/minute) (14). This device has greater accuracy than the widely used 
Yamax SW-200 pedometer which records all steps taken within 1% under controlled conditions 
and has shown a strong relationship (r = 0.80-0.93) with accelerometers (20, 176). 
     Doyle et al. (49) assessed the validity and reliability of the Omron HJ-700IT pedometer in a 
laboratory setting for twenty young adults (35.0 years, BMI of 23.1 kg/m2) who completed two 
trials of treadmill walking in which they averaged 3,305.8 + 198.7 steps. Each trial was for 15 
minutes at walking speeds of either 2.5 or 3.0 mph. The criterion measure was manually counted 
steps. The Omron pedometer was carried in three different locations (e.g., shirt pocket, belt clip 
at the hip, and pants pocket) in random order while the Yamax Digi-Walker SW-200 pedometer 
was worn only on the belt at the right hip. There were no significant differences in total steps 
counted by the Omron pedometer and the criterion measure. However, there was a significant 
difference in steps counted by the Yamax pedometer (p < 0.001) and the criterion measure. The 
Pearson's correlation coefficient of manually counted steps compared to the Omron pedometer 
was 0.991, 0.998, and 0.958 for the shirt, belt and pants pocket, respectively, while the Yamax 
was 0.725. Percent error for the Omron pedometer was 0.04, 0.15, and 0.67%, respectively, for 
the three locations compared to -4.21% for the Yamax SW-200. Thus, the Omron pedometer 
proved to be a highly accurate and reliable in measuring continuous walking activity in a 
laboratory setting (49). 
     In order to assess the effects of age and obesity on pedometer accuracy Melanson et al. (103) 
examined 259 subjects who walked at self-selected speeds on a treadmill using a Yamax SW-200 
pedometer. The researchers also evaluated the accuracy of two spring-levered pedometers (e.g., 
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Walk-4-Life LS-2500 and Step Keeper HSB-SKM) compared to a piezoelectric pedometer (e.g., 
Omron HJ-100) at slow walking speeds (e.g., 1.0-2.6 mph) on a treadmill using 32 subjects. 
Regarding the Yamax SW-200, self-selected walking speed and pedometer accuracy 
demonstrated an inverse relationship with increasing age, weight and BMI. Crouter et al. (45) 
also reported an inverse relationship between BMI and pedometer accuracy with the same 
pedometer. In agreement with prior research, which has studied generally healthy and special 
populations (18, 109, 131), Melanson et al. (103) noted the slowest self-selected walking speeds 
(2.0 mph and below) were associated with the lowest pedometer (e.g., Yamax SW-200) 
accuracy. Specifically, the magnitude of this pedometer’s step count error increased with age, 
from 3% in 18-30-year-old subjects (average speed of 2.9 mph) to 19% in the subjects 61-70 
years who walked at an average speed of 2.3 mph. Given that older adults demonstrate the 
slowest self-selected walking speeds, it is not surprising that increasing age was the best 
predictor of decreased pedometer accuracy. The Omron HJ-100 pedometer was superior to both 
spring-levered pedometers at all walking speeds tested (e.g., 1.0-2.6 mph). For example, at 1.8 
mph the Omron recorded 97.8 + 9.6% of counted steps, which was significantly greater than the 
Walk-4-Life (52.1 + 38.7%) or Step Keeper (73.4 + 36.7%) pedometers, respectively (103). 
     Doyle et al. (50) compared the validity and reliability of the Omron HJ-700IT to the Yamax 
Digi-Walker SW-200 pedometer when worn by 60 young adults (31.7 years, BMI of 23.7 kg/m2) 
who walked at a self-selected pace for 30 minutes on an indoor track. The subjects averaged 
3,450.2 + 311.4 steps at an average speed of 3.3 + 0.6 mph. The criterion measure was manually 
counted steps. The Omron pedometer was carried in three different locations (e.g., shirt pocket, 
belt clip at the hip, and pants pocket) in random order while the Yamax Digi-Walker SW-200 
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pedometer was worn only on the belt at the right hip. There were no differences between both 
pedometers and manually counted steps. The Pearson's correlation coefficient of manually 
counted steps compared to the Omron pedometer was 0.995, 0.992, and 0.968 for the shirt, belt 
and pants pocket, respectively, while the Yamax was 0.786. Percent error for the Omron 
pedometer was -0.04, 0.18, and 0.43%, respectively, for the three locations compared to - 3.11% 
for the Yamax. This study demonstrates the accuracy of the Omron pedometer, when worn in 
various positions, in measuring step counts that reflect the physical activity recommendations of 
the ACSM (50). 
     Recently, Holbrook et al. (74) examined the validity and reliability of the HJ-720ITC 
pedometer at prescribed and self-selected walking speeds in 47 young, healthy adults (24 years, 
BMI of 25 kg/m2) on a walking course. The walking course required subjects to stop at road 
crossings, perform up and downhill walking on grass as well stair climbing. Subjects walked for 
100 meters at three speeds (e.g., slow, moderate or brisk) and walked 1 mile at a self-selected 
pace. The pedometer was clipped and worn at the right and left hip, the mid-back, as well as the 
right and left pockets. Validity was assessed by having a subset of 31 subjects complete the 1 
mile walking course twice and reliability was ascertained by allowing subjects to randomly 
select different pedometers for each trial they completed. Aside from the backpack position, the 
Omron HJ-720ITC demonstrated an absolute percent error of less 3.0% regarding pedometer 
wear sites and a coefficient of variation of less than 3.3% at any designated or self-selected 
walking speed (74).     
     These results indicate that piezo-electric pedometers provide superior validity and reliability 
when compared to popular spring-levered mechanisms (e.g., Yamax Digi-Walker SW-200). This 
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holds true at slower speeds (common in the elderly population) (103, 109), during self-selected 
speeds (49, 103) and when the pedometer is tilted at an angle, which may be the case for 
individuals who are overweight and obese (45, 65). Given that elderly individuals self-select 
slower walking speeds than younger adults, piezo-electric pedometers are recommended for the 
older population (46, 65, 103). Furthermore, piezo-electric pedometers should be utilized in CRP 
whose participants are typically overweight or obese (e.g., 88.4%) and older (e.g., 57 + 11 years) 
(15). 
Omron HJ 720-ITC: a novel pedometer with enhanced data collection 
 
     The Omron HJ-720 ITC pedometer provides time and date-stamped, hour-by-hour step-count 
data (delineated between aerobic and non-aerobic steps). This permits researchers to readily 
assess inter-day step variations and with a concise questionnaire, researchers can determine 
whether steps are accumulated via occupational, domestic or leisure time activities. This 
pedometer can distinguish whether subjects are accumulating steps through fragmented or  
continuous bouts at a pace of > 60 steps/minute continuously for 10 minutes (e.g., aerobic steps) 
(115). These measurements could be used to ascertain if a given amount of total or continuous 
physical activity is needed for disease prevention, health, weight loss, or effective risk factor 
management. The pedometer also has an activity flag that indicates that if the user has pursued 
any movement for a given hour it is worn. This activity flag allows researchers to determine how 
compliant subjects are regarding the number of hours the pedometer is worn each day. In order 
to reduce non-step artifacts, the pedometer does not record movement of less than 4 seconds of 
duration (115). 
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     The subject’s ambulatory activity information can be downloaded, via a supplied USB cable, 
using the accompanying Omron B1 software to any computer using either the Windows XP or 
Millennium operating systems. The software program presents step counts in a bar graph format 
that is delineated between aerobic and non-aerobic steps (see Figure 1). Activity patterns can be 
displayed in this manner on a daily, weekly, monthly or yearly basis. In addition, users can enter 
daily goals for each of the aforementioned step count parameters and the software program 
provides feedback regarding the percentage achievement level attained. The pedometer data 
displayed includes: overall steps, aerobic steps and aerobic walking time on an hour-by-hour 
basis. All of this information can be readily converted to an Excel spreadsheet or PDF format for 
statistical analysis. Each time the activity record is downloaded, it is seamlessly integrated with 
prior records in order to provide a continuous overview of step counts. As long as the data are 
downloaded before 42 consecutive days have elapsed, a given individual’s detailed ambulation 
activity could be monitored continuously for as long as they are willing to wear the pedometer.  
 
 
 
 
 
 
 
 
 
 42 
 
 
Figure 1: shot of an individual’s daily steps counts using the Omron B1-link software 
 
     Overall, the Omron HJ -720 ITC pedometer demonstrates exceptional accuracy, validity and 
unprecedented detailed step count data allowing researchers to more readily assess an 
individual’s inter and intra-day activity patterns. Three studies have shown the ability of this 
pedometer to assess and increase step counts for individual who were obese, diagnosed with 
Type 2 diabetes or have intellectual disabilities (123, 128).   
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Step indices for the general population and phase II CRP participants 
 
     In 2001, Tudor-Locke and Myers (171) reviewed 32 studies which involved cross-sectional, 
prospective cohort and intervention study designs. The authors noted that daily step count for 
healthy younger adults varied between 7,000-13,000 steps/day. Healthy older adults accumulate 
6,000-8,500 steps/day while individuals with disability and chronic illnesses accumulated 3,500-
5,000 steps/day. The inverse relationship between daily step counts and age has been confirmed 
by other researchers (33, 101).      
     Recently, Tudor-Locke and Bassett (181) designated the initial daily step indices for healthy 
adults using the following five classifications: (1) < 5,000; sedentary, (2) 5,000-7,499; low 
active, (3) 7,500-9,999; somewhat active, (4) > 10,000; active and (5) > 12,500; highly active. 
The authors noted that a minimum of a 2,500 steps/day increase (e.g., improving one activity 
designation) is required to alter health outcomes favorably. Interestingly, this increment in step 
counts corresponds with the results from a recent meta-analysis of studies which used 
pedometers to enhance habitual activity levels and quantified that the typical increase in daily 
step counts is 2,491 for pedometer users versus control subjects (30). 
     The popular daily step count recommendation of 10,000 has been advocated to provide 
significant health benefits, such as weight loss and blood pressure improvements (78, 141). The 
amount of physical activity required to accumulate 10,000 steps does not require 30 minutes of 
continuous physical activity during which individuals walk 3-4,000 steps (173). Prior research 
using pedometers has shown that 3-4,000 steps should be accumulated to meet the ACSM 
activity guidelines in the context of the following parameters: they are of at least moderate 
intensity (e.g., > 100 steps/minute), accumulated in at least 10 minutes bouts and in addition to 
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steps taken to perform the activities of daily life (e.g., approximately 5-6,000 steps/day) (176, 
183, 184). This step count range combined with the sedentary designation of 5,000 steps would 
necessitate 8-9,000 steps/day and is associated with meeting the current ACSM activity 
guidelines (94, 171). This step count goal may be more practical for older populations and those 
with chronic diseases than 10,000 steps/day.   
     The step indices proposed by Tudor-Locke and Bassett are not applicable to healthy children 
or individuals with chronic diseases (181). Additional research has examined the average daily 
steps for several special populations, including individuals with peripheral vascular disease 
(4,100-5,300 steps/day), chronic obstructive pulmonary disease (3,800 steps/day), diabetes 
(6,600 steps/day), congestive heart failure (4,900 steps/day) and the elderly (6,500 steps/day) (1, 
144, 145, 173). Furthermore, several pedometer based studies have noted an inverse relationship 
between daily step counts and increasing age which is associated with an increased prevalence of 
the aforementioned chronic diseases (28, 33, 145, 181).  
     Seniors comprise the majority of the phase II CRP population, which has a high prevalence of 
multiple chronic diseases and exhibits a sedentary lifestyle (1, 15, 26). Thus, as opposed to 
encouraging them to attain an 8-10,000 daily step count, which would require them to almost 
double their daily activity level, a more reasonable physical activity goal would be to increase 
their daily activity levels significantly (e.g., 2-2,500 steps/day) versus their baseline activity level 
(173). CRP participants could accomplish this activity goal through increased activities of daily 
life or short bouts of moderate intensity walking. This would indicate that they had increased 
their activity designation (e.g., from sedentary to low active). This recommendation would 
concur with the AHA exercise training recommendations for CRP participants, which states that 
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“the total amount of activity is more important for health than the performance of high intensity 
exercise” (56). This statement is supported by research demonstrating a dose-response 
relationship between overall activity and reductions in CHD mortality (16, 25, 71, 90). The 
preliminary results from a pedometer-based intervention study indicate that individuals with 
CHD may be capable of sustaining the “somewhat active” designation regarding daily step 
counts for a prolonged period of time (76).  
     Although several studies have used pedometers to assess the average daily step counts for 
participants in phase III CRP, only two published studies have examined phase II CRP 
participants. Savage et al. (138) examined 107 individuals (76% men, 63 years, BMI of 29 
kg/m2) for seven days after their initial phase II CR exercise training session. Subjects 
demonstrated significantly higher step counts on CRP versus non-CRP days (7,387 + 3,387 
versus 5,315 + 3,336 steps/day; p < 0.0001). The authors noted the results for non-CRP days are 
likely indicative of these individuals’ typical activity patterns and categorizing their activity 
levels using the aforementioned step indices would indicate that 57% were sedentary, 21% low 
active, 10% somewhat active, 7% active and 5% highly active. These activity patterns do not 
compare favorably with the results of 23 healthy adults (70% women, 38 years and BMI 27.7 
kg/m2) who wore a pedometer for a year during which 45% of the cohort was classified as active 
or highly active (38). The phase II CRP participants’ sedentary activity designation on non-CRP 
days warrants additional exercise counseling and monitoring to enhance their activity levels on 
these days to enhance the effectiveness of regular exercise on cardiac and all-cause mortality 
outcomes (138).  
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     The typical individual participating in a phase II CRP is sedentary and counseling them to 
increase their activity levels all the way up to the “active” category (e.g., 10,000 steps/day) 
appears to be impractical, since this would essentially require them to double their daily step 
counts. Instead, a more pragmatic activity objective for this population may be the upper range 
of “low active” or the lower range of the “somewhat active” designation (e.g., 7-8,000 steps/day) 
by the end of their phase II CRP enrollment. This would require an increase in daily step counts 
of 2-3,000, which has been demonstrated to be achievable in individual with chronic conditions 
and is associated with improvements in primary risk factors for CHD (8, 76, 107, 143, 174).  
Walking as a means to improve CRF levels of phase II CRP participants 
 
     Walking is the most commonly performed leisure activity by middle age and older adults in 
the United States (61, 150). It is readily accessible, requires no special clothing or equipment to 
perform and can be accurately quantified with pedometers (20, 61, 171). Walking can be 
performed in domestic, occupational or recreational settings at a frequency, intensity and 
duration that is self-determined (73). In the healthy population as well as in individuals with 
CHD, walking has been shown to have a favorable effect on primary risk factors for CHD which 
reduces the risk of cardiovascular events (61, 107, 143). Ahlbom et al. (6) reported that walking 
approximately 30 minutes 4-5 times/week is associated with a decreased incidence of heart 
attacks in healthy populations as well as individuals with known CHD. Furthermore, walking 
pace has been associated with significantly lower CHD risk in men and women in age-adjusted 
and multivariate models (97, 160) 
     The AACVPR, AHA, ACC and ACSM recommend walking as an appropriate activity for 
CRP participants to perform in an unsupervised capacity at low to moderate exercise intensities 
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(e.g., 2.0-3.5 mph walking pace) (16, 152). Walking at a self-selected pace has not been 
associated with a greater incidence of myocardial infarctions for individuals with CHD (190). 
Walking is an exercise modality that is feasible for individuals who participate in CRPs given 
their especially low cardiorespiratory fitness (CRF) levels. Ades et al. (4) reported on the VO2peak 
in 2,896 patients entering phase II CR. Men demonstrated a significantly higher VO2peak values 
of 19.4 + 6.1 ml/kg-1 . min-1 versus 14.5 + 3.9 ml/kg-1 . min-1 for women. Low CRF levels 
demonstrate an independent, linear increase in risk for MI, unstable angina, coronary 
revascularization and all-cause mortality (25, 121). The low CRF level of the phase II CR 
population indicates that many activities of daily life that may be generally considered low 
intensity activity would require a high percentage of their functional capacity. Since a typical 
walking speed of 3.0 mph requires an oxygen consumption of 11.5 ml/kg-1 . min-1, this would 
require 60% and 80% of the maximal aerobic capacity for the average male and female, 
respectively, entering a phase II CRP. Given their low baseline CRF levels, walking speeds of 
2.0-3.0 mph should be sufficient to engender improvements in CRF levels for individuals with 
CHD. A recent meta-analysis of randomized clinical trials using walking at self-selected speeds 
as the sole activity intervention noted an improvement in CRF levels of approximately 10% 
(111). The importance of improving the CRF of this population is underlined by the results from 
Yu et al. (197) reported that CR patients who failed to achieve an exercise capacity > 4 METs 
had a relative risk (RR) of 16.5 for cardiac mortality, regardless of whether the patient had 
experienced an MI prior to CRP participation. 
      Regular walking is an appropriate form of routine exercise for individuals with CHD to 
pursue in an unsupervised capacity given its practicality, suitability for various functional 
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capacities and ability to increase CRF levels, while not posing any increased cardiac event risk 
when performed at low to moderate intensities (61).   
Pedometer-based walking programs result in improvements of the primary risk factors for 
CHD 
 
     Primary risk factors for coronary heart disease are considered clinical designations or lifestyle 
characteristics that independently expedite the CHD process. The primary risk factors for CHD 
include: physical inactivity, type 2 diabetes, hyperlipidemia, hypertension, obesity, smoking and 
a family history of CHD (11, 132). Approximately 90% of individuals with CHD have at least 
one of the following primary risk factors: hypertension, hyperlipidemia, current smoker or 
diabetes (64, 87). Ades et al. (5) noted that in 2,896 patients entering phase II CR the prevalence 
of HTN was 62%, obesity 40%, smoking 19.4%, and diabetes 24%. Cholesterol results were not 
reported. Given the low CRF level in this population (e.g., approximately 17 ml/kg-1 ·  min-1) it is 
reasonable to assume the majority of subjects were sedentary. Interestingly, studies have 
demonstrated there is an inverse relationship between daily step counts and an individual’s 
number of primary risk factors (33, 55). For example, Farmer et al. (55) noted that individuals 
with 0 or 1 primary risk factor had a baseline activity level approximately 1,700 steps higher 
than subjects with 2 or 3 or more risk factors.  
     Currently there is insufficient evidence to indicate that a given step count is associated with 
reductions in cardiac or all-cause mortality. However, a significant amount of research has been 
performed using pedometers to measure the average daily steps associated with improvements in 
primary risk factors for CHD. The research to date indicates that increases of at least 2,500 
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steps/day are required to favorably alter health outcomes (181). This would be equivalent to 
walking an additional 1.5 miles/day (190).  
     Hypertension is clinically defined as resting systolic blood pressure of at least 140 mmHg, or 
a diastolic blood pressure of at least 90 mmHg, or currently taking anti-hypertensive medication, 
and is considered a risk factor for CHD as well as stroke (11). Moreau et al. (107) studied 15 
postmenopausal women (53 years, BMI of 29.5 kg/m2) who were provided with incrementally 
greater target step counts above their baseline activity level periodically until they achieved a 3 
kilometer increase in daily walking. They also recorded their daily step counts on a log sheet. 
Subjects increased their daily step counts by 4,300 to 9,700 and demonstrated a significant 
reduction in their systolic blood pressure at 6 weeks (e.g., 5 mmHg) and even further at 24 weeks 
(e.g., 11 mmHg). The blood pressure lowering effects of exercise were sustained for individuals’ 
already taking anti-hypertensive medications and were especially profound for individuals 
classified with mild hypertension (107).  
     Additional research in Japan examined 30 hypertensive men (48.5 years, BMI of 24.6 kg/m2) 
who were encouraged to walk at least 10,000 steps a day over a 12 week period. Subjects were 
not taking anti-hypertensive medication. During the study, subjects averaged 13,510 + 837 
steps/day (baseline activity levels were not reported) and their systolic and diastolic pressures 
decreased 10 and 8 mmHg, respectively. In addition, sympathetic nerve activity was reduced 
significantly in experimental group, while their VO2max increased significantly from 26.1 to 29.5 
ml/kg-1 ·  min-1 (p < 0.05). Seventeen control subjects (48.7 years, BMI of 25.2 + 0.9 kg/m2) 
walked 5,790 + 458 steps/day and demonstrated no changes in either of the aforementioned 
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variables. Neither systolic nor diastolic blood pressure changes were correlated with daily step 
counts (78). 
     Hyperlipidemia is considered a primary risk factor for CHD and stroke (132). Total 
cholesterol (TC) levels > 200 mg/dl, a TC/HDL-C ratio > 5.0 or a LDL/HDL > 3.0 constitutes 
hyperlipidemia (11). Sugiura et al. (158) reported that 14 sedentary women (49 years, BMI of 
22.3 kg/m2) who sustained an increase in their daily steps of approximately 2,400 (e.g., 6,500 to 
8,900 steps/day) over a 24 month period had significant improvements in their HDL-C (3.7 
mg/dL), coupled with a significant decrease in TC (25 mg/dL) while demonstrating a non-
significant 1 kg weight loss. LDL values decreased 19 mg/dL, although the change was not 
significant. A control group of 13 women (48 years, BMI of 22.6 kg/m2) did not alter their daily 
step counts during the study and demonstrated no changes in any lipoprotein sub-fraction. 
Multiple regression analysis revealed that although no relationship existed at baseline, at 24 
months daily step counts were inversely related to TC and the TC/HDL-C ratio and positively 
related to HDL-C. The authors noted that the changes in the subjects’ lipoprotein profiles were 
attributable, in part, to changes in daily steps taken.  
     Type 2 diabetes is clinically diagnosed when an individual’s fasting blood glucose levels are 
equal to or greater than 126 mg/dl on two separate occasions and is considered a CHD equivalent 
(11). Impaired fasting glucose (IFG) requires a fasting blood sugar level greater than 100 but less 
than 125 mg/dl on two separate occasions and is considered a precursor to Type 2 diabetes and a 
risk factor for CHD. Swartz et al. (159) examined a group of 18 sedentary, obese women (53 
years, 35.0 BMI of kg/m2) with impaired glucose tolerance. After they increased their daily step 
count from 4,952 to 9,200 steps per day over an 8 week period, they exhibited significant 
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improvements in glucose tolerance as well as systolic and diastolic pressure (e.g., decreased 6 
mmHg). These outcomes occurred independently of changes in body mass, BMI, body fat, waist 
circumference, waist/hip ratio.  
     An individual is considered obese with a BMI > 30 kg/m2, if men and women have a 
waist/hip circumference ratio > .95 and  > .86 or a waist circumference > 40 inches and  > 35 
inches, respectively (11). Pedometer based studies have consistently demonstrated an inverse 
correlation between daily step counts and the prevalence of overweight or obesity (33, 75, 165), 
as well as various indices of adiposity including BMI, percentage body fat, waist circumference 
and waist/hip circumference ratio (33, 75, 77, 172). For instance, Thompson et al. (167) observed 
that 80 female subjects (50 years, BMI of 26.0 kg/m2) who wore a pedometer for one week 
exhibited an inverse relationship between steps/day and percentage body fat (r = - 0.713), BMI (r 
= - 0.417), waist (r = - 0.616) and hip (r = - 0.278) circumference and waist/hip ratio (r = - 
0.652). Prior research has suggested that 50% of the variance in percentage body fat can be 
explained by differences in pedometer-based physical activity (165).  
     Schneider et al. (143) reported that sedentary, overweight or obese adults (47 years, BMI of 
33.5 kg/m2) who adhered to a 36-week exercise intervention program increased their daily step 
from 5,115 to 10,390. Their body weight (4.5 kg), BMI (1.6 kg/m2), percentage body fat (3.2), 
fat mass (4.7 kg), waist circumference (3.1 cm) and hip circumference (2.9 cm) decreased 
significantly. 
     The results of these pedometer-based studies indicate that increases in walking positively 
affects each modifiable risk factor for CHD, which are especially prevalent for individuals 
participating in phase II CRPs (1). Preliminary results of the daily step counts for seniors (i.e., > 
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65 years, 3,500 steps/day) and individuals entering a phase II CRP participants (5,000 steps/day) 
indicate these individuals are sedentary (138, 178). A prior pedometer-based intervention for 
seniors with no and up to three chronic diseases (e.g., CHD, HTN, type 2 diabetes, etc.) indicate 
they increase their absolute activity levels approximately 20% (range of 600-2,000 steps/day) 
versus baseline over 24 weeks (55). There is a paucity of research involving seniors with 
multiple chronic diseases and it has yet to be determined if the reported increase in steps/day 
required to alter risk factors favorably (e.g., 2,500), which would represent at least a 50% 
absolute increase in activity levels, is feasible for this population.  
The use of motion sensors in phase II and II CRPs 
 
     To date, only two studies have used pedometers to examine the physical activity patterns of 
participants in Phase II CRPs (133, 138). Rosneck et al. (133) evaluated the activity patterns of 
98 subjects in phase II CR who were randomly assigned to wear an open or closed Yamax SW-
200 pedometer. Individuals assigned to wear the open pedometer, self-recorded their step counts 
each day. Subjects had to participate in the CR for a minimum of 7 weeks. Both groups were 
asked to gradually increase their activity level on non-CRP days but were not given individual 
step counts goals. The mean daily steps during phase II CR enrollment were similar between the 
open and closed groups, 6,340 versus 5,694, respectively. Although baseline step counts were 
not reported, it appears that regular participation in phase II CR does not meet the activity 
guidelines advocated by the AACVPR, AHA, ACC and ACSM for individuals with CHD (16, 
71, 152) 
     Savage et al. (138) assessed the physical activity levels of 107 individuals (76% men, 63 
years, BMI of 29 kg/m2) for seven days using a Walk4Life pedometer after their initial phase II 
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CR exercise training session. Subjects had significantly higher step counts on CR versus non-
CRP days (7,387 + 3,387 versus 5,315 + 3,336 steps/day; p < 0.0001) with no differences based 
on gender. Given that non-CRP days are probably indicative of these individual’s typical activity 
patterns, this variable was used for primary analysis. A stepwise linear multiple regression 
revealed that the variable showing the strongest correlation with total daily step counts on non-
CRP days was VO2peak (r = 0.49, p < 0.0001). There was also a significant inverse relationship 
between non-CRP day step counts and the following: diabetes mellitus, waist circumference, 
BMI, age, glucose, total co-morbidity score, weight and resting systolic blood pressure. HDL-C 
was positively correlated with step counts on non-CRP days. Using stepwise multivariate 
analysis, VO2peak, HDL-C and diabetes mellitus each correlated with average daily step counts. 
These results indicate that higher daily step counts were associated with a more favorable CHD 
risk profile (138). Using the step indices proposed by Tudor-Locke and Bassett (181), participant 
step counts on non-CRP days indicated that 57% were sedentary, 21% low active, 10% 
somewhat active, 7% active and 5% highly active. The authors noted the results for non-CRP 
days are likely indicative of these individuals’ typical activity patterns and that their sedentary 
classification warrants additional exercise counseling and monitoring to enhance their activity 
levels on these days (138).  
     Several studies have employed motion sensors to assess the activity levels of phase III CRP 
participants. Jones et al. (83) assessed the physical activity levels of 25 men (60 years, BMI of 
29.6 kg/m2) using an Actigraph GT1M accelerometer. Subjects wore the accelerometer for seven 
days and recorded the duration, intensity and mode of any exercise activity they completed in an 
exercise log. Overall, the subjects averaged 6,907 + 510 steps/day while expending 466 + 38 
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kcal/day via physical activity. Step counts were significantly higher on CRP versus non-CRP 
days (e.g., 10,087 + 631 vs. 5,287 + 520). The step counts on non-CRP days were very similar to 
the activity levels of participants in phase II CR on non-CRP days (e.g., 5,315 + 3,336 steps/day) 
(138). Individuals who performed home exercise as well as CRP exhibited significantly higher 
step counts than CRP-only exercisers (e.g., 7,933 + 604 vs. 5,277 + 623). Lastly, individuals who 
were employed accumulated significantly more steps on CR days than those who were retired 
(e.g., 6,271 + 701 vs. 3,938 + 537). 
     Izawa et al. (79) examined exercise maintenance and LTPA six months after 109 participants 
(64 years, BMI of 23.2 kg/m2) completed a 5-month supervised phase II CRP. All participants 
had sustained a previous MI. Over 83% of patients continued to exercise for more than 6 months 
after completing phase II CRP. The remaining subjects who did not were considered the control 
group. LTPA was assessed by having each subject wear a Kenz Lifecorder pedometer for one 
week, which estimated daily EE. The exercise group walked significantly more steps per day 
than the non-exercise group (9,252 + 3,047 versus 4,246 + 2,025 steps/day) and expended more 
than twice as many calories (1,940 versus 875 kcal/day). The frequency, intensity and duration 
of activity were not documented in the exercise group nor were step counts compared for phase 
III CRP versus non-CRP days. Each group increased VO2peak significantly (experimental; 4.6 
ml/kg . min-1, controls; 3.7 ml/kg . min-1) but there was no difference between groups (8).  
     Izawa et al. (80) conducted the only randomized clinical trial using pedometers forty-five 
patients (64 years, BMI of 22.4 kg/m2) who had just completed six months of supervised 
exercise in a Japanese-based phase II CRP were randomly assigned to a self-monitoring 
approach (SMA) group or a control group. Baseline daily step count values were 6,564 + 1,115 
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for the SMA versus 6,282 + 1,986 for the control group. During the next six months, the SMA 
group monitored their activity levels using a Lifecorder pedometer and recorded them in an 
exercise log. Both groups regularly participated in phase III CR exercise sessions three times a 
week. At the conclusion of the study, the SMA group’s mean daily step counts were 10,458 + 
3,310 versus 6,922 + 3,192 in the control group (80). These results show that pedometers can 
enhance activity levels for prolonged periods of time for individuals with CHD.  
     It is important to note that both of the aforementioned studies by Izawa et al. (79, 80) were 
conducted in Japan and used different phase II CRP protocols than those used in the United 
States. For instance, the patients’ exercise intensity was maintained “at an anaerobic threshold 
heart rate” which is likely higher than the 60-75% HRmax prescribed in the U.S. Furthermore, 
exercise maintenance after completing a phase II CRP is remarkably higher in Japan than in the 
U.S. (83 vs. 50%) (70, 79). This may result from the fact that CRP participation is covered by 
Japanese national health insurance for six months versus the United States where it may covered 
for only 6 to 36 visits (79). Thus, the financial hurdle for CR participation is considerably less 
for the Japanese populace. Also, the average body mass index (BMI) values of the participants in 
this study were considerably lower than that of CRP participants in the U.S (e.g., 23 versus 28 
kg/m2). The average steps/day in the exercise group was close to 10,000 which researchers have 
reported is equivalent to expending 332, 383 and 432 kilocalories while walking at 
approximately 2.6, 3.2 and 3.9 mph for an individual weighing 55 kg (80). Furthermore, this 
level of EE meets the upper range of physical activity recommended by national clinical 
guidelines and is associated with coronary lesion regression (14, 112). Although the study did 
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not provide specific details for how the exercise group attained their exercise volume, it does 
indicate this level of physical activity is safe and attainable for Japanese individuals with CHD.  
     Ayabe et al. (13) examined 77 subjects (69% men, 68 years, BMI of 27.0 kg/m2) enrolled in a 
phase III CRP.  The amount of time they spent in light (< 3 METs), moderate (3-6 METs) and 
vigorous (> 6 METs) physical activity was determined by a uni-axial accelerometer (Lifecorder). 
Subjects had been participating in the program for an average of 5.4 years and walking was the 
only form of physical activity pursued during the phase III CRP. The weekly amount of physical 
activity EE was 1,597 + 846 kcal/week, indicating significant between-subject variability. 
Weekly EE was significantly higher in men (e.g., 1,778 kcal) versus women (e.g., 1,197 kcal) 
but after adjustment for weight, the gender difference disappeared. Activity levels were 
significantly higher on CRP days than on non-CRP days; 299 + 161 versus 177 + 113 kcal/day. 
These values are substantially lower than reported by Jones et al. (83) which could be due to the 
use of a different accelerometer. Subjects also spent significantly more time in low and moderate 
intensity activities on CRP versus non-CRP days (low intensity; 59.7 + 19.8 versus 49.3 + 19.3 
minutes, moderate activity; 26.4 + 20.4 versus 10.5 + 14.6 minutes). These caloric expenditures 
are comparable to prior studies that assessed EE during phase II and III CRPs (136, 139). These 
results confirm that these participants are not meeting the exercise recommendations for 
individuals with CHD (11, 16, 152). During the remainder of the day when subjects were not 
participating in a CRP, they did not have a significant difference in physical activity levels on 
CRP or non-CRP days (13). Less than half of participants surpassed 1,500 kcal/week and only 
16% exceeded 2,220 kcal/week; activity levels believed to be associated with arresting coronary 
artery progression and minimal regression, respectively (14, 112). The average daily energy 
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expenditure for this population could have been elevated to 2,200 kcal if subjects consistently 
walked at 3.0 mph for 30 minutes on days they did not attend the CRP. 
     Recently, a follow-up analysis of this cohort was used to discern the daily steps counts 
required for secondary prevention of CHD (14). Overall, average daily step counts were 6,752 + 
2,659, with 8,499 + 3,173 steps accumulated on phase III CRP days and 5,491 + 2,805 steps on 
non-phase III CRP days. The latter value is very similar to the activity levels of participants on 
non-CRP days in phase II CR (e.g., 5,315 + 3,336 steps/day) (138). The number of daily step 
counts was strongly related to total physical activity energy expenditure (r = 0.92, p < 0.001) and 
time spent in moderate to vigorous intensity physical activity (r = 0.85, p < 0.001). These results 
indicate that walking is the most commonly performed activity for leisure time as well as 
structured exercise activity. The average daily step counts which corresponded to 144, 214 and 
314 kcal/day (reflective of weekly values of 1,000, 1,500 and 2,200 kcal, respectively), were 
5,046, 6,470 and 8,496 steps/day, respectively. Therefore, the authors concluded that daily step 
counts of 6,500 and 8,500 correspond to the physical activity level associated with arresting 
coronary artery lesion progression and minimal reversal (14, 112).  
     The majority of studies to date indicate that the average physical activity level of phase II or 
phase III CRP participants is appreciably less than recommended for individuals with CHD 
(13,83, 136). This result appears to be attributable to low physical activity levels on days when 
patients do not attend a structured exercise program. Many authors have commented on this and 
suggested that CRPs should encourage participants to accumulate additional physical activity on 
days they do not attend the program (13, 83, 136). Presently, no research study on phase II CRP 
participants has used pedometers to examine whether they can increase LTPA on non-CRP days.  
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Integrating pedometers into CRPs 
 
     A model for how pedometers may be use by allied health professionals to enhance their 
ability to provide effective physical activity monitoring and counseling exists in the form of 
telephone counseling. The basis of this counseling method involves an allied health professional 
who periodically contacts a patient, via the telephone, to assess their progress in managing a 
given chronic disease. A typical conversation may entail the case manager inquiring if the patient 
is regularly taking their prescribed medications, eating the recommended diet and monitoring the 
symptoms of the given disease. The case manager provides positive feedback and reinforces the 
lifestyle strategies the patient can purse to self-manage their condition(s) (76, 130). For example, 
telephone counseling has proven to be effective in counseling patients with congestive heart 
failure (CHF) regarding management of their body weight. The program involves a case manager 
who provides patients with CHF a body weight scale and a daily log to record their weight after 
being discharged from the hospital. Once a week for 12 successive weeks, a case manager calls 
the patient who reports their present body weight. If body weight has increased by three pounds 
or more, the case manager asks directed questions to determine the cause of the weight gain and 
provides advice to prevent further weight gain or schedule a physician visit, if necessary. A 
typical call lasts approximately 5-10 minutes. This program has been proven to significantly 
decrease hospital re-admissions, heart failure hospital days and in-patient heart failure costs were 
45% lower for individuals with CHF undergoing telephone case-management care versus typical 
care (130).  
     Pedometers have been used in a similar manner with physicians or cardiologists providing a 
pedometer to their patients classified as low or moderate risk. This population has shown a 
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similar reduction in adverse cardiac events or mortality whether they have participated in a home 
or center-based exercise program (82). Stovitz et al. (156) observed 21 subjects who received a 
pedometer after brief physician endorsement (e.g., 1 minute) during which they were asked to 
incrementally increase their average daily steps counts by 400 each week for 9 weeks. Subjects 
received three follow-up phone calls from a health educator and significantly increased (by 2,089 
steps/day) their mean daily step counts from a baseline level of 6,779 + 4,690 steps/day.    
     Preliminary results indicate that pedometers can be used in a manner similar to telephone 
counseling to increase activity levels. Houle et al. (76) studied 32 subjects who received a 
pedometer and an exercise log book upon discharge from a hospital after suffering a CHD event. 
In the experimental (E) group, a certified nurse specialist (CNS) contacted patients intermittently 
to assess their activity goals and gradually encouraged them to increase their activity levels. 
Control (C) subjects received usual care and were asked to record their daily exercise activity 
while wearing a blinded pedometer. Baseline step counts were similar (E; 6,116 + 2,985 versus 
C; 6,020 + 3,325 steps/day; p = 0.767) between the two groups. Three months after 
hospitalization, the two groups significantly increased their daily step counts (E; 9,285 + 3,359 
versus C; 8,447 + 3,974 steps/day). At 6 months after hospitalization, the experimental group 
further increased their average daily step counts by 109 steps/day compared to a 1,501 steps/day 
decrease in the control subjects (76). These are preliminary results as the study is designed to last 
1 year. 
     Combined, these studies show the promise of using pedometers coupled with practical 
monitoring and counseling strategies to enhance physical activity levels. Pedometers can provide 
an objective, cost effective tool that can be readily be integrated into the behavior counseling 
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strategies utilized in traditional CRPs with minimal participant burden. These devices can 
complement pre-existing counseling strategies to positively influence the physical activity  levels 
of phase II CRP participants.   
Summary 
 
     The vast majority of individuals eligible for a CRP do not enroll in one. Individuals who 
regularly participate in a phase II CRP do not perform the recommend volume of physical 
activity recommended by the AACVPR, AHA, ACC and ACSM. Yet research consistently 
demonstrates favorable cardiac and all-cause mortality outcomes in this population.      
     Activity guidelines for this population indicate home based exercise programs are appropriate 
for low and moderate risk individuals with CHD (16, 152). Research indicates that home based 
programs are as efficacious as center-based CRP for the management of risk factor and mortality 
outcomes (82, 153). Regarding individuals with CHD, walking is the most common physical 
activity (14). It expends a significant amount of calories, requires no special equipment and it is 
convenient to perform. Further, epidemiological studies confirm its effectiveness in reducing 
cardiac and all-cause mortalities (84, 85, 97). The integration of pedometers could provide CR 
clinicians with a cost-effective, valid assessment of their patient’s physical activity patterns. In 
addition, pedometers provide individuals with easy to understand activity recommendations and 
motivate them to increase their activity levels. Therefore, future research should determine 
whether the addition of pedometers to phase II CRPs can increase physical activity levels, 
especially on non-CRP days. Higher activity levels in this population would likely lead to 
improved primary risk factor management, decreased cardiac events and reduced cardiac and all-
cause mortality.  
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Introduction 
 
     Individuals with coronary heart disease (CHD) who participate in phase II cardiac 
rehabilitation program (CRPs) demonstrate reduced cardiac and total mortality (26, 92, 189, 
195). This may be due to the fact that regular aerobic exercise provides a number of 
physiological and psychological benefits related to effective CHD management (23, 58, 59, 60, 
69, 67, 112, 159). Only 10-20% of eligible patients enroll in a phase II CRP due to logistical and 
financial challenges coupled with poor referral rates by physicians (157, 161). Furthermore, 
about one-half of patients who enroll no longer exercise on a regular basis 1 year after 
completing a phase II CRP (3, 26, 159). These shortcomings results in avoidable mortality, 
morbidities and healthcare expenditures (67, 113, 159). 
     Phase II CRPs offer patients with CHD the opportunity to pursue an appropriate exercise 
program, coupled with education, to effectively manage their primary risk factors (121, 135). 
The American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR), 
American College of Cardiology (ACC), American Heart Association (AHA) and the American 
College of Sports Medicine (ACSM) recommend that patients with CHD perform a minimum of 
30 to 60 minutes of moderate intensity activity at least 5 times/week, coupled with an increase in 
daily lifestyle activities (11, 16, 71, 153). These recommendations are based on the dose-
response relationship between overall activity levels and CHD (3, 67, 118). A typical phase II 
CRP entails 30-60 minutes of moderate intensity physical activity 3 times a week and thus 
participants cannot meet the aforementioned physical activity recommendations if this is the only 
time they exercise. Thus, additional unsupervised exercise is required on the days these 
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individuals do not attend a phase II CRP (e.g., non-CRP days) in order to meet the physical 
activity levels recommended for this population (5, 16, 92). 
     Research indicates that approximately 75% of phase II CRP participants do not perform an 
adequate amount of physical activity on the days they attend a CRP when caloric expenditures 
are used to measure physical activity (27, 31). This observation may explain why some clinical 
studies have reported that phase II CRP participation results in modest or no improvements in 
risk factor modification (31, 126, 159). 
     A core component of phase II CRPs is to pursue effective counseling strategies that permit 
their patients to meet the physical activity guidelines and maintain them after completing the 
program (3, 26, 165). Attaining this activity objective should help reduce physician visits due to 
heart complications, lead to better management of risk factors, reduce the likelihood of future 
cardiac events and enhance functional capacity (3, 54, 70, 113, 119). Presently, the counseling 
methods and exercise component used in traditional phase II CRPs to enhance and monitor the 
short and long-term activity patterns of its participants are insufficient.    
     Pedometers offer an objective, accurate, valid and reliable means to measure ambulatory 
activity with minimal participant burden (18, 19, 20, 141, 174, 176). They permit self-monitoring 
and instant feedback on ambulatory activity, which may improve self-efficacy and motivate 
individuals to increase their activity levels (30, 34, 42, 77, 143, 156). Walking is the most 
prevalent form of leisure time physical activity among seniors and thus pedometers should 
provide an accurate indication of their overall activity levels (151). 
     Researchers have established that increased daily step counts are inversely related to adiposity 
(e.g., body mass index, percentage body fat), body weight and waist/hip circumference (36, 37, 
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51, 75, 165). Increased daily step counts have been reported to improve blood glucose 
management (158, 195), blood lipid profiles (145, 157) and lower systolic blood pressure values 
(107, 145, 170). These results indicate that higher physical activity levels can help individuals 
more effectively manage the modifiable risk factors for CHD (15, 157). Although the majority of 
these studies were conducted with healthy young to middle-aged adults, pedometer programs 
designed to improve activity levels are also effective in older adults (55, 129). 
     Recently, pedometers using a piezo-electric mechanism have been developed. Specifically, 
the Omron HJ-720ITC pedometer contains a dual-axis accelerometer that accurately records step 
counts whether it is upside-down, slanted or perpendicular to the ground (91, 131). This 
pedometer is valid and reliable in younger and older individuals (49), in laboratory settings at 
designated treadmill speeds (e.g., 2.0-4.0 mph) and on flat surfaces at self-selected speeds (e.g., 
slow, normal, and fast) (48, 49, 74). This device is more accurate than the Yamax SW-200 
pedometer, which has a spring levered mechanism and is widely used in research (19, 174). In 
addition, the accuracy of the Yamax SW-200 decreases with increasing BMI and waist 
circumference, whereas the accuracy of the Omron does not (45). The Omron HJ-720ITC 
pedometer provides time and day-stamped, hour-by-hour step-count data, which can differentiate 
between aerobic (i.e., steps taken at a pace of 60 per minute for at least 10 minutes 
consecutively) and non-aerobic steps (115). 
     The purpose of this study was to determine if the use of a pedometer coupled with an exercise 
diary and step goals will change the physical activity patterns of adults who participate in a phase 
II CRP on their non-scheduled CRP days compared to those receiving typical treatment.  
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Methods 
Patients 
     Seventy male and twenty female adults between the ages of 46 and 86 years volunteered to 
participate in the study. Inclusion criteria for the study were: enrollment in a Mercy Health 
Partners cardiac rehabilitation program (CRP), the ability to follow the study protocol, (i.e., no 
presence of dementia), and the ability to walk at a speed of at least 2.0 mph. The latter 
requirement is due to the fact that pedometers display poor accuracy at slower walking speeds 
(i.e., < 2.0 mph) (22, 46, 103). All patients recently had at least one of the following cardiac 
events or procedures performed: myocardial infraction (n = 26), percutaneous transluminal 
coronary angioplasty (PTCA) (n = 44), coronary artery bypass surgery (CABG) (n = 34), 
implantable cardioverter defibrillator (n = 2), and/or valve replacement (n = 7). The 
aforementioned diagnoses were not mutually exclusive. Additional inclusion criteria were a risk 
stratification of low or moderate risk (according to AACVPR guidelines), and the ability to 
perform continuous walking (no cardiovascular or orthopedic contraindications to aerobic 
exercise training). 
     Patients were excluded from the study if they: 1) were classified as high risk (according to 
AACVPR guidelines), 2) had a documented history of dementia that could preclude them from 
following the study protocol, 3) demonstrated unusually high step counts (e.g., > 8,000 
steps/day) at baseline (138), or 4) required an assistive walking device. Patients must have 
received clearance for at least 20 supervised phase II CR visits from their insurance provider so 
that their activity patterns could be monitored for a sufficient period of time.  
     The phase II CRP began with an orientation in which a registered nurse and/or a exercise 
physiologist documents each patient’s medical history, medication regimen and physical activity 
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patterns before he/she begins supervised exercise participation, including electrocardiogram 
observation. During the orientation, a registered nurse informed eligible patients about the 
voluntary nature of the study and its requirements and potential risks (see Appendix A). Next, 
they were given an informed consent form (see Appendix B). After the patient had read and 
signed the informed consent form, they were given a copy for their personal use. The original 
informed consent was kept in the patient’s medical history file and a copy was maintained by the 
principal investigator in a locked file cabinet in the CRP’s main office. The informed consent 
form as well as the study protocol was reviewed and approved by the Institutional Review 
Boards (IRBs) at the University of Tennessee and Mercy Health Partners, Inc., respectively. 
During the orientation, all patients were encouraged to accumulate additional physical activity on 
the days they did not attend the phase II CRP. 
Study design 
 
     Phase II CRP enrollment typically entails 4-12 weeks of supervised exercise and education 
(e.g., cardiovascular risk factor reduction and lifestyle modification) for approximately one hour 
three times a week (Monday, Wednesday, Friday). Phase II CRP participants usually exercise 
three days a week and attend a 30-60 minute education session (consisting of seven different 
topics) once a week. The minimum length of time a patient was enrolled in the study protocol 
was 20 CRP sessions, or approximately seven weeks. This time period allowed them the 
opportunity to attend each education session. The maximum length of time a participant was 
enrolled in the study was 36 phase II CRP sessions, or approximately 12 weeks. The length of 
phase II CRP enrollment is dependent on several factors including: the patient’s medical 
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diagnosis, functional progress and insurance provider coverage. The exercise sessions were 
offered in the morning and afternoon with patients choosing to participate in one or the other.  
     During the first six months of data collection, subjects who chose to participate in the 
afternoon exercise sessions were assigned to the control group and given a blinded pedometer. 
Conversely, patients who elected to participate in the morning session were designated as the 
experimental group. This design was reversed for the last six months of data collection. This 
design was chosen so as to minimize the chance that patients in the control group (i.e., those with 
the blinded pedometer) would interact with experimental patients, who could read their 
pedometer display. 
     Subjects assigned to the experimental group were given a step count log (see Appendix C) 
and were instructed to record the total number of steps they accumulated at the end of each day. 
Control patients were informed that they would not be able to view their step counts but they 
would be given a report that explained their activity levels at the end of their CRP enrollment 
(See Appendix D). 
     At the end of the phase II CRP orientation, each patient was given an Omron HJ-720 ITC 
pedometer (Omron, Inc., Dalian City, China). The beginning of phase II CRP participation was 
chosen for the onset of the study since patients had received medical clearance from their 
cardiologist and the registered nurse had verified they were capable of resuming their typical 
daily activities. Each patient was informed that the pedometer was capable of measuring the 
number of steps they take on a daily basis and that an objective of the study was to monitor their 
physical activity patterns throughout their participation in the CRP. Patients were given 
instructions regarding how the pedometer was to be carried (e.g., in either the left or right front 
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pocket) or worn (e.g., placed in the supplied pedometer holder and attached to the belt or top of 
their pants at the mid-thigh).  
     The Omron HJ-720 ITC pedometer contains a microchip with enough memory to store 42 
days of time and date-stamped, hour-by-hour step count data. This pedometer discriminates 
between aerobic and non-aerobic steps and includes a software program which displays and 
archives the activity information. Aerobic steps are recorded whenever a subject walks for at 
least ten consecutive minutes at a pace of at least 60 steps/minute. The pedometer allows 
researchers to monitor how compliant subjects are by displaying the number of hours the 
pedometer is worn each day. For a given day, the initial hour a subject began wearing the 
pedometer was determined if they registered at least 50 steps for that hour. The last hour they 
wore the pedometer for a given day was noted when they registered less than 50 steps for a 
particular hour. In order to reduce non-step related step artifacts, the pedometer does not record 
any movements that last less than 4 seconds in duration. Therefore, minor movements that occur 
in isolation are not recorded (115).  
     The Omron HJ-720 ITC pedometer has been validated for younger and older populations (46, 
48), in laboratory settings at designated treadmill speeds (e.g., 2.0 - 4.0 mph) (65, 72), and on flat 
surfaces in free-living environments at self-selected speeds (e.g., slow, normal, and fast) (48, 11, 
15, 16). It also provides valid steps counts for stair climbing at a typical pace (e.g., 80 
steps/minute) (14). It provides equal accuracy in step counts among normal weight, overweight 
and obese individuals (131) and when worn in various positions (e.g., in either front pocket or in 
a designated clip at the midline of either thigh) (16, 17, 131). This device is more accurate than 
the widely used Yamax SW-200 pedometer, which uses a spring-lever design.           
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     Patients were instructed to designate a standard area (e.g., nightstand or vanity) where they 
would place the pedometer immediately before they went to bed to increase the likelihood they 
would be visibly prompted to wear the pedometer each day. Patients in the experimental group 
were instructed to keep their step diary in the same area. The pedometer was programmed with 
the appropriate time, the patient’s weight and stride length. Stride length was determined as 
recommended by Omron Inc. (115). Specifically, patients walked 10 steps using their typical 
gait; the total distance covered during the walk was divided by 10 to determine stride length. 
During the baseline period, pedometer accuracy (acceptance criteria: + 2 steps) was verified by 
having each patient take 20 steps in a straight line in a designated area in the CRP facility (171). 
Patients in the experimental group were encouraged to repeat this test on their own and advised 
to report inaccurate pedometer readings.  
     Patients were instructed to wear the pedometer during all waking hours except showering or 
participating in water-based activities. They were also instructed not to change their typical 
leisure-time physical activities during their initial week of participation in the phase II CRP. 
Previous research has indicated that middle aged adults (e.g., 47 years) need to wear a pedometer 
for three days to achieve an intra-class correlation (ICC) reliability coefficient of 0.80 for weekly 
step counts (177). Togo et al. has noted that the elderly population (e.g., > 65 years) may require 
additional days of monitoring to reliably estimate their annual activity since intra-individual 
variations may be greater than in younger populations due to more flexible daily schedules in 
retirement (169). These researchers monitored the physical activity patterns of older subjects, 
average age of 71 + 4 years, for a year and noted that if the season and day of the week were 
accounted for, an ICC of 0.80 could be attained with periods of 8 and 4 consecutive days of 
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observation for men and women, respectively (169). Thus, the initial seven days of phase II CRP 
enrollment was used to attain an accurate baseline measurement of the patients enrolled in the 
study. 
Protocol 
     After patients had completed the baseline period, their pedometer data were downloaded to 
establish a digital record of their overall and aerobic step counts during their first week of phase 
II CRP enrollment (i.e., baseline step counts). For the experimental group, overall step counts 
were compared with the values recorded in their step count log each week to verify that they 
were keeping accurate records of their activity patterns. For both groups, pedometer wear time 
was noted to ensure that each patient was wearing the pedometer at least 12-14 hours/day. Those 
who did not consistently wear the pedometer for this time period (n=11) were eliminated from 
the study.  
     Pedometer data for all patients were downloaded each week. All patients were asked each 
week if they experienced any untoward cardiac events outside of the CRP and if they felt their 
stamina was improving. All patients were informed each week that the physical activity 
recommendations for individuals with CHD is to accumulate 30-60 minutes of moderate 
intensity activity five or more days of the week and thus they needed to perform additional 
exercise on the days they did not attend the phase II CRP (16, 71, 153). Overall and aerobic steps 
counts were averaged for CRP days (e.g., M, W and F) and non-CRP days (T, R, Sa. and Su.).  
     Patients had to attend at least two exercise sessions per week to maintain their eligibility for 
the study. If they did not, they were eliminated from the study (n = 11). An exception was made 
regarding this eligibility criteria if the patient went on vacation, had to undergo a non-cardiac 
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related procedure (e.g., cataract surgery) and for weeks that involved a holiday during which the 
phase II CRP was closed. When patients missed a phase II CRP exercise session, that session 
(e.g., CRP day) and the following day (e.g., non-CRP day) were omitted from their step count 
data collection. Data collection was resumed when they attended their next exercise phase II 
CRP session. Collecting data in this manner allowed for an equal number of monitored days 
between patients who never or rarely missed a phase II CRP session versus those who did. When 
patients failed to wear a pedometer for a weekday, the missing data were replaced by using the 
mean of the remaining weekdays. Missing weekend days were replaced with the alternate 
weekend day (86).           
    Patients in the experimental group were given individualized step count goals, which have 
been shown to result in positive health outcomes (30, 181). After baseline step counts were 
established, these patients were encouraged to increase their average overall step counts by 5-
10% on non-CRP days during the next week. This increment in step counts has been proven to 
be attainable and safe in senior populations (e.g., > 70 years of age) (55). They could accomplish 
the goal via increased activities of daily life (e.g., performing additional housework, parking 
further away when performing errands, etc.) or short continuous walks of 5-10 minutes, which 
have been demonstrated to increase daily walking time (193). This protocol, which gradually 
increases the volume of exercise over time, follows the AACVPR and AHA recommendations 
for this population (3). Specifically, the AHA states that the amount of physical activity 
performed is more important than the exercise intensity for health improvements in this 
population, although moderate intensity activities should be pursued (56). Patients were asked if 
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the step count goals were reasonable and if so, how they planned to attain it. The step count goal 
was written on their exercise log for the appropriate upcoming seven day period. 
     If the patients reached their step count goal, then they were encouraged to repeat it for the 
next week. The following week, they were encouraged to increase their step counts by 5-10% 
and this process continued until patients had increased their average step counts on non-CRP 
days by approximately 2,000 to 2,500 steps per day, compared to their baseline value. 
Thereafter, they were asked to maintain this increase in activity level on non-CRP days for the 
remainder of their enrollment in the phase II CRP. This incremental improvement in daily step 
counts has been suggested as a minimum requirement to favorably alter health outcomes (181). 
When patients did not attain their step count goal, they were asked if the goal was reasonable, in 
order to help determine why they did not reach the goal. Then, additional strategies were 
employed in an attempt to meet the goal during the next week. 
     Patients in the control group were reminded each week what the activity recommendations 
were for individuals with CHD. Specifically, they were informed that a minimum of 30 to 60 
minutes of moderate intensity physical activity should be performed at least five, preferably all, 
days of the week for individuals with CHD (16, 71, 153). Thus, they were consistently instructed 
that they should regularly perform additional exercise on the days they did not attend the phase II 
CRP.   
Medical history 
     Primary risk factors for coronary heart disease (CHD) were determined by self-report and the 
patient’s medical history. These included hypertension, high cholesterol, type 2 diabetes, family 
history, smoking, obesity and a sedentary lifestyle. The standards for each primary risk factor 
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were based on the AHA guidelines (11). Type 2 diabetes was ascertained by self-report or if the 
patient was prescribed blood sugar management medications. Obesity was defined as a body 
mass index (BMI) > 30 kg/m2, based on the direct measurement of height and weight. Physical 
activity status was ascertained through self reported activity levels. Medications were 
documented by the registered nurse or exercise physiologist during the orientation (each patient 
was required to bring their prescription medication to the orientation). Working status, cardiac 
events, cardiac procedures and the number of days from hospital discharge until phase II CRP 
entry were determined from in-patient hospital records.   
Data analysis 
 
     Statistical analyses were performed using SAS 9.2 software for Windows (Cary, NC) and 
SPSS 14.0 (Chicago, IL) and an alpha of < 0.05 was used to denote statistical significance. 
Values are presented as mean + standard deviation for the patient physical characteristics, step 
counts and baseline data (see Tables 1 and 2). Two sample t-tests were used to compare the 
baseline physical characteristics between genders as well as the control and experimental groups. 
Normality was tested by the Kolmogorov-Smirnov test and the Satterthwaite estimation was 
employed to account for non-homogeneity of variance.  
     The patients’ daily overall and aerobic step counts were averaged each week for CRP (e.g., 
M, W and F) and non-CRP days (e.g., T, R, Sa. and Su.). Two sample t-tests were used to assess 
differences between genders and groups regarding baseline step counts for CRP and non-CRP 
days. Baseline step counts for CRP and non-CRP days were compared based on the presence of 
each risk factor with the exception of sedentary behavior.  
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     The study protocol required that patients enrolled in a phase II CRP for a minimum of seven 
and maximum of twelve weeks. 70 patients completed seven weeks of the phase II CRP. Seven 
subjects completed between seven and twelve weeks. A total of 55 subjects completed 12 weeks 
of the phase II CRP. Thus, two separate statistical analyses were performed to account for CRP 
enrollment differences.  
     Step count results for the first seven weeks of phase II CRP enrollment were analyzed using a 
2 x 7 repeated measures ANOVA (with group as the between factor and time as the within 
factor) to assess differences between groups and time and their interaction regarding changes in 
overall and aerobic step counts on CRP and non-CRP days. If there was a significant interaction 
effect, the groups were analyzed separately using a one-way repeated measures ANOVA. This 
permitted the identification of significant differences between designated points in time (e.g., 
week 2 versus baseline, week 3 versus baseline, etc.) for overall or aerobic step counts. Next, 
each time point (e.g., week 1, week 2, etc.) was analyzed separately to determine if there were 
significant differences between the control and experimental groups. In the event of a significant 
effect for any variable, a Bonferroni corrected post hoc comparison was performed.  
     In order to account for the variations in the number of weeks of enrollment in the phase II 
CRP, each patient’s last week of enrollment was designated as their “completion” variable. A 
repeated measures ANOVA was used analyzing only baseline and “completion” time points. 
Thus, if a patient was enrolled for 8 weeks in the phase II CRP, their step count values for week 
8 were compared to their baseline values. This statistical analysis revealed the effects of the 
intervention, regardless of how long patients were enrolled in the phase II CRP.     
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Results 
 
Patient participation 
 
     Ninety four patients met the inclusion criteria and voluntarily agreed to participate in the 
study. One patient withdrew from the study after being assigned to the control group. Three 
subjects reported adverse cardiac episodes (e.g., unstable angina) and were eliminated from 
participation in the study. A total of five pedometers malfunctioned and would not permit step 
count data to be retrieved resulting in those patients being discontinued from study participation. 
Four patients lost their pedometer. Eleven patients were excluded because they did not wear the 
pedometer consistently. The remaining subjects (n = 70) completed seven weeks of the phase II 
CRP. Between weeks seven and twelve of phase II CRP participation, three subjects resumed 
full-time work and elected to discontinue the program, two subjects passed away and 10 subjects 
either decided they had progressed sufficiently physically to graduate from the program and 
chose to exercise independently or pursue the phase III CRP. Therefore, 55 patients completed 
12 weeks of the phase II CRP. Figure 2 displays the flow of patients in the study. Participants 
wore the pedometer for 14.1 + .9 hours throughout the study. They consistently wore it as only 
20 person-days of missing data were noted.  
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Figure 2: Flow of patients through the study 
Subjects who met initial study 
criteria and were randomized 
based on their preferred exercise 
time (n=94) 
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Lost pedometer (n=2) 
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Lost pedometer (n=2) 
 
Completed 7 
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program (n=6) 
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Personal or phase II CRP decision 
that they could graduate from the 
program (n=4) 
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(n=27) 
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Baseline characteristics 
 
     The patients’ baseline characteristics categorized by gender and study group designation are 
presented in Table 1. Patients were predominantly male (76%) with a mean age of 69 + 9 years 
(range, 46 to 86 years). Patients typically enrolled in the phase II CRP about 5 weeks after they 
were discharged from the hospital. Significant baseline differences were noted between men and 
women for height and weight. There were no differences in any other physical characteristic 
between genders, or between the experimental and control groups. Patients were taking a mean 
of seven medications, with beta-blockers (85%) and statins (92%), being the most prevalent (data 
not shown). There were no differences in prescription medication usage between genders or 
groups. Approximately 71% percent of the patients were retired. 
     Both genders and groups had an average of four primary risk factors, with hypertension, high 
cholesterol and sedentary behavior being the most prevalent. The presence of primary risk 
factors for the overall group was similar to previous results regarding the phase II CRP 
population (15). However, 81% of the subjects in the present study were hypertensive versus 
60% noted in previous studies; this may be due to the fact that the present population was 
approximately 10 years older (5, 15). Women and experimental patients were more likely to have 
undergone percutaneous transluminal coronary angioplasty (PTCA) while more men underwent 
coronary artery bypass graft (CABG) surgery. The proportion of subjects undergoing the 
aforementioned procedures is similar to previous results of patients entering a phase II CRP (5). 
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Table 1. Physical and medical history characteristics of participants 
 
Characteristic  Men  
(n = 53) 
Women 
 (n = 17) 
Exp.  
(n = 36) 
Controls 
 (n = 34) 
All subjects 
 (n = 70) 
Age (yr) 67.2 + 9.7 70.5 + 7.3 68.1 + 9.0 67.8 + 9.5 67.8 + 9.1 
Height (m) 1.78 + 0.1 1.61 + 0.06* 1.73 + 0.09 1.75 + 0.09 1.74 + 0.10 
Weight (kg) 91.5 + 20.9 75.9 + 15.0* 86.0 + 20.8 89.2 + 20.7 87.7 + 20.6 
BMI (kg * m2) 28.8 + 6.5 29.1 + 5.0 28.5 + 5.6 29.3 + 6.6 29.0 + 6.1 
Ejection fraction (%) 49 + 10 55 + 9 52 + 10 48 + 10 50 + 9 
Days from hospital 
discharge to CR enrollment 
39 + 25 34 + 17 36 + 24 41 + 23 38 + 23 
Retired 66% 89% 73% 71% 71% 
Primary risk factors 3.9 + 1.1 3.9 + 1.2 3.8 + 1.1 4.0 + 1.3 3.9 + 1.2 
  Obesity 40% 39% 43% 39% 41% 
  Hypertension 82% 78% 81% 81% 81% 
  High cholesterol 84% 78% 81% 83% 82% 
  Sedentary  82% 100% 85% 85% 85% 
  Smoking 20% 28% 16% 22% 23% 
  Type 2 diabetes 29% 22% 23% 33% 29% 
  Family history 33% 44% 30% 36% 36% 
Cardiac procedure      
  CABG 44% 24% 39% 38% 39% 
  PTCA 43% 65% 56% 41% 49% 
  Other 13% 11% 5% 21% 12% 
 
Data reported as mean + standard deviation 
* Significant difference between men and women (p < 0.05) 
Other surgical procedures included implantable cardioverter defibrillator or valve procedure 
Baseline activity levels 
     Baseline physical activity patterns are depicted in Table 2. Overall daily average step counts 
were 3,797 + 1,755 with 355 + 694 aerobic steps. Subjects averaged 105 steps per minute when 
accumulating aerobic steps and there were no differences in this value between genders or 
groups. Men took significantly more overall steps per day than women (p < 0.01), but similar 
aerobic steps. This pattern was sustained for overall steps counts on CRP (p < 0.05) as well as 
non-CRP days (p < 0.05). At baseline, participants demonstrated a significantly higher overall 
step counts on CRP versus non-CRP days (p < 0.01), but similar aerobic steps. This pattern was 
sustained regardless of gender or group assignment. 
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Table 2:  Baseline physical activity patterns of participants based on gender and group 
designation 
 
Characteristic  Men  
(n = 53) 
Women 
 (n = 17) 
Exp.  
(n = 36) 
Controls 
 (n = 34) 
All subjects 
 (n = 70) 
Total steps/day 3,996 + 1,764* 3,136 + 1,455 4,071 + 1,781 3,508 + 1,551 3,797 + 1,755 
Aerobic steps/day 438 + 652 351 + 836 488 + 766 327 + 440 355 + 694 
Total steps/day on 
CRP days 
4,435 + 1,572*† 3,561 + 1,424† 4,515 + 1,661† 3,962 + 1,434† 4,247 + 1,573† 
Aerobic steps/day 
on CRP days 
428 +  622 302 + 646 483 + 722 275 + 427 398 + 626 
Total steps/day on 
non-CRP days 
3,667 + 1,679* 2,818 + 1,205 3,763 + 1,780 3,175 + 1,372 3,461 + 1,611 
Aerobic steps/day 
on non-CRP days 
445 + 701 387 + 791 491 + 904 324 + 457 431 + 718 
 
Data reported as mean + standard deviation 
* Significant difference between men and women (p < 0.05) 
† Significant difference between CRP and non-CRP days (p < 0.01) 
     Baseline overall step counts were similar for both groups on CRP and non-CRP days (p = 
0.11 and p = 0.145, respectively). This pattern was also apparent for aerobic steps (p = 0.23 and 
p = 0.47, respectively). 
Statistical results for non-CRP days 
     Figure 3 illustrates the changes in overall and aerobic steps on non-CRP days (Tuesday, 
Thursday, Saturday and Sunday) for the experimental and control groups during phase II CRP. 
70 subjects completed seven weeks of the phase II CRP, while 55 completed 12 weeks.      
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Figure 3: A comparison of changes in weekly overall and aerobic step counts between 
experimental (E) and control (C) subjects on non-CRP days 
 
* p < 0.0001 experimental versus control 
‡ p < 0.0001 versus baseline experimental step counts (overall or aerobic) 
 
 
     The repeated measures ANOVA of overall step counts on non-CRP days revealed there was a 
significant (p < 0.001) group by time interaction. This indicates that the experimental patients 
increased their overall steps counts significantly more and at a faster rate on non-CRP days than 
control subjects. The post hoc analysis divided the two groups, which were analyzed with a one-
way repeated measures ANOVA. Experimental patients demonstrated significantly (p < 0.0001) 
higher overall and aerobic step counts for weeks 2-7 versus baseline. Interestingly, the 
experimental patients attained a plateau by week 4 as there were no differences in their step 
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counts between weeks 4 and 7 (see Figure 1). In contrast, control patients had no change in 
overall steps throughout weeks 2-7. Post hoc analyses compared the groups to one another at 
each time point. The groups were similar (p = 0.145) at baseline but they were significantly 
different at every other time point (p < 0.001).  
     There was also a significant (p < 0.001) group by time interaction for aerobic step counts on 
non-CRP days. The groups were divided and analyzed using a one-way repeated measures 
ANOVA. Experimental patients demonstrated a significant (p < 0.001) time effect for aerobic 
steps as each time point was different (p < 0.05) from baseline. Conversely, the control group 
displayed similar (p = 0.475) aerobic steps for weeks 2-7.  
     The 2 by 2 repeated measures analysis comparing the groups’ baseline and “completion” 
values demonstrated that there was a significant group interaction (p < 0.0001), indicating that 
overall step count changes were different between the two groups. There was a significant 
increase in overall steps on non-CRP days for the experimental patients (p < .001) while there 
was no difference for controls (p = 0.446).  
      There was a significant interaction (p < 0.0001) for time concerning aerobic step counts on 
non-CRP days, indicating the groups did not increase their aerobic step counts at the same rate. 
Next, the groups were split and compared by time, which revealed that experimental patients 
increased their aerobic step counts significantly (p < 0.0001) and the control patients did not      
(p = 0.558).  
     The average weekly step counts for overall and aerobic steps on non-CRP days for both 
groups are depicted in Table 3. 
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Table 3: Weekly averages for overall and aerobic step counts for non-CRP days 
 
 Experimental Control 
 Overall steps Aerobic steps Overall steps Aerobic steps 
Week 1 3,763 + 1,780  491 + 904 3,175 + 1,372 324 + 457 
Week 2 4,709 + 2,080 *† 1,063 + 1,313 *† 3,292 + 1,900 331 + 524 
Week 3 5,058 + 2,027 *† 1,233 + 1,326 *† 3,335 + 1,409 428 + 837 
Week 4 5,693 + 2,102 *† 1,585 + 1,564 *† 3,299 + 1,423 362 + 783 
Week 5 5,512 + 1,898 *† 1,435 + 1,321 *† 3,172 + 1,475 245 + 454 
Week 6 5,772 + 2,166 *† 1,726 + 1,399 *† 3,267 + 1,688 312 + 570 
Week 7 5,777 + 2,127 *† 1,726 + 1,635 *† 3,137 + 1,661 257 + 403 
Week 8 5,678 + 2,149 *† 1,726 + 1,519 *† 3,415 + 1,773 258 + 432 
Week 9 5,770 + 2,493 *† 1,868 + 1,672 *† 3,327 + 1,707 191 + 457 
Week 10 5,893 + 2,235 *† 1,740 + 1,276 *† 3,732 + 2,160 443 + 684 
Week 11 6,264 + 2,582 *† 2,087 + 1,545 *† 3,643 + 1,922 421 + 557 
Week 12 6,400 + 2,623 *† 2,158 + 1,566 *† 3,364 + 1,960 281 + 582 
 
Data reported as mean ± standard deviation 
* versus control step counts (overall or aerobic) (p < 0.001) 
† versus baseline experimental step counts (overall or aerobic) (p < 0.001) 
 
Statistical results for CRP days 
 
     Figure 4 illustrates the changes in overall and aerobic steps on CRP days (Monday, 
Wednesday and Friday) for the experimental and control groups during the phase II CRP. 
     The repeated measures ANOVA for overall steps on CRP days indicated that there was not a 
significant (p = 0.095) group by time interaction. There was a significant (p < 0.001) time effect, 
as each week was different from baseline. In terms of a group effect, post hoc paired 
comparisons between the experimental and control groups showed that that they were similar at 
baseline (p = 0.11) and that only weeks 3 and 7 were different from one another.  
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Figure 4: A comparison of changes in weekly overall and aerobic step counts between 
experimental (E) and control (C) subjects on CRP days 
 
* p < .05 experimental versus control (overall) 
† p < .001 versus baseline control step counts (overall or aerobic) 
‡ p < .001 versus baseline experimental step counts (overall or aerobic) 
 
     The group by time interaction was not significant (p = 0.312) for aerobic steps on CRP days. 
There was a slight difference (p = 0.033) between the groups. There was also a significant (p < 
0.01) increase over time, as both groups consistently increased their aerobic step counts from 
baseline until week 7.   
     The 2 by 2 repeated measures analysis comparing the groups’ baseline and “completion” 
overall step counts for CRP days indicated there was a significant (p = 0.025) interaction and 
thus changes over time were different by group. Next, the groups were split and each of them 
demonstrated significant (p < 0.01) increases over time. The experimental patients increased 
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their overall step counts on CRP days by 2,516 and the control patients 1,579. As noted, the 
groups were similar at baseline (p = 0.11) but not at phase II CRP completion (p = 0.007). 
     There was no significant group interaction (p = 0.237) but there was for time (p < 0.001) for 
both groups concerning aerobic step counts on CRP days. The overall group increased their 
aerobic step counts on CRP days by 1,250. 
     The average weekly step counts for overall and aerobic steps on CRP days for both groups are 
depicted in Table 4. 
Table 4: Weekly averages for overall and aerobic step counts on CRP days 
 
 Experimental Control 
 Overall steps Aerobic steps Overall steps Aerobic steps 
Week 1 4,515 + 1,661 484 + 722 3,962 + 1,434 275 + 427 
Week 2 5,684 + 2,268 † 913 + 1,322 † 4,637 + 1,987 * 483 + 776 * 
Week 3 6,232 + 2,091 † 1,609 + 1,922 † 4,707 + 2,072 * 628 + 1,019 * 
Week 4 5,951 + 2,092 † 1,442 + 1,584 † 4,895 + 1,917 * 797 + 1,015 * 
Week 5 6,202 + 1,923 † 1,339 + 1,152 † 5,100 + 1,937 * 1,086 + 1,181 * 
Week 6 6,673 + 2,253 † 1,763 + 1,647 † 5,493 + 2,211 * 1,209 + 1,224 * 
Week 7 6,557 + 2,148 † 1,769 + 1,419 † 5,320 + 1,854 * 1,150 + 1,069 * 
Week 8 6,521 + 1,994 † 1,823 + 1,222 † 5,393 + 2,042 * 1,143 + 1,008 * 
Week 9 6,748 + 2,266 † 1,655 + 1,392 † 5,209 + 2,100 * 1,034 + 805 * 
Week 10 6,917 + 2,265 † 1,870 + 1,340 † 5,277 + 2,347 * 1,230 + 997 * 
Week 11 7,390 + 2,984 † 2,056 + 1,527 † 5,344 + 2,630 * 1,261 + 910 * 
Week 12 7,290 + 2,738 † 2,071 + 1,446 † 5,529 + 2,381 * 1,401 + 1,107 * 
 
Data reported as mean + standard deviation 
* versus baseline control step counts (overall or aerobic) (p < 0.01) 
† versus baseline experimental step counts (overall or aerobic) (p < 0.01) 
 
Discussion  
 
     This is the first study to demonstrate the effectiveness of pedometers in conjunction with step 
count goals and an exercise diary in patients enrolled in a phase II CRP. The overall increase in 
daily steps counts (e.g., 2,500) is associated with health benefits for healthy and special 
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populations. Experimental subjects demonstrated the ability to increase their activity levels on 
the days they attended a phase II CRP as well as the days they did not, predominantly through an 
increase in aerobic step counts. The pace of the aerobic stepping (i.e., 112 steps/minute) which 
falls within the range of 3-6 METs. Thus, it appears that pedometers facilitate phase II CRP 
participants to increase their overall activity levels versus patients receiving standard care.     
     Savage et al. (138) contend that step counts on non-CRP days during their first week of 
enrollment are indicative of an individual’s typical activity pattern. They assessed 107 
individuals for seven days after their initial phase II CRP exercise training session. Patients 
demonstrated significantly higher step counts on CRP versus non-CRP days (7,387 versus 5,315 
steps/day; p < 0.0001). The authors noted that 62% of the patients would be considered sedentary 
(i.e., they accumulated less than 5,000 steps per day) and that additional exercise counseling and 
monitoring is warranted to enhance their activity levels on non-CRP days (138). In the present 
study, patients averaged 3,461 steps per day on non-CRP days at baseline. This non-CRP step 
count is markedly lower than that reported by Savage et al. (138), which may be attributable to 
the older age (68 versus 63 years) of the patients in the sample. Alternatively, it could result from 
a design characteristic of the pedometer used in the present study, which does not record 
movements that last less than 4 seconds in duration (115). Baseline overall steps were not 
significantly different between the experimental and control groups (4,071 versus 3,508). This 
slight difference may be attributable to the fact that experimental patients could view their steps 
counts and were required to record them in a step count log, which has been noted to 
significantly increase steps/day versus wearing a blinded pedometer only (39). Overall, 85% of 
the patients in the present study would be classified as sedentary (i.e., < 5,000 steps/day) (181). 
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These results underline the importance of identifying effective exercise monitoring and 
counseling strategies so that phase II CRP patients will more readily adopt and maintain exercise 
patterns that improve their functional capacity and subsequently reduce their risk for cardiac and 
all-cause mortality (54, 187). 
Pedometer based studies in phase II CRP    
    
     Pedometers have been used in a limited capacity in phase II (133, 138) and III CRPs (13, 14, 
79, 80, 83). Phase II CRPs are insurance-based, electrocardiogram (ECG) monitored exercise 
and education based programs. Phase II patients exercise at designated time periods for 
approximately 30-60 minutes, three times a week for 4-12 weeks during which time their 
exercise program is consistently progressed. Phase III CRPs are self-pay and include patients 
who have successfully completed 20-36 phase II CRP exercise sessions. Phase III patients are 
allowed to pursue supervised but non-monitored exercise sessions. 
     Rosneck et al. (133) evaluated the activity patterns of 98 patients in a phase II CRP who were 
randomly assigned to wear an open or closed Yamax SW-200 pedometers. Patients assigned to 
wear an open pedometer self-recorded their step counts each day. Both groups were asked to 
gradually increase their activity level on non-CRP days but were not given individual step counts 
goals. Baseline step counts, patient characteristics nor differences between CRP and non-CRP 
days were reported. The mean daily step counts during phase II CRP enrollment were similar 
between the open and closed groups, 6,397 versus 5,694, respectively, which was greater than 
the present study (5,876 versus 4,084, experimental versus control groups, respectively). Prior 
research using pedometers has shown that 3-4,000 steps/day equates to about 30 minutes of 
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moderate intensity walking, which is the minimum recommended for healthy adults and those 
with CHD (13, 22, 153, 192). These steps should be of at least moderate intensity (e.g., > 100 
steps/minute) and accumulated in bouts of at least 10 minutes in duration and  in addition to 
steps taken to perform the activities of daily life (e.g., approximately 5-6,000 steps/day) (182, 
184). The mean daily step count for experimental subjects who completed the entire phase II 
CRP was 6,739. Therefore, it appears that even when activity levels at the conclusion of phase II 
CRP exercise participation is taken into account, the physical activity levels of phase II CRP 
participants do not meet the activity guidelines advocated for individuals with CHD (11, 71, 
153).  
     The use of pedometers provides a novel approach to complement traditional strategies to 
monitor and enhance the activity levels of phase II CRP participants. Prior randomized clinical 
trials have demonstrated that the use of pedometers coupled with daily step count goals leads to 
significant increases in activity levels (e.g., 2,500 steps/day) in general and in special 
populations, but this strategy has not been utilized in the phase II CRP population (30, 34, 55, 
143, 170). 
Activity levels on non-CRP days 
 
     In the present study, experimental patients (n =36) demonstrated a significant (p < 0.001) 
increase in their overall and aerobic step counts for weeks 2 through 7 versus the control group 
(n=34). The majority of the increase in overall steps occurred by week four, and step counts 
tended to plateau thereafter. This may be attributable to the fact that some experimental patients 
achieved the designated increase in overall step counts (i.e., 2,000) on non-CRP days early in the 
program and further increases were not encouraged. In the experimental patients, the average 
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change in overall and aerobic step counts at the completion of the program on non-CRP days was 
remarkably similar to CRP days (2,616 + 1,752 versus, 2,704 + 1,644, respectively). Thus, these 
patients were willing and able to independently replicate their activity patterns on days they 
pursue structured, monitored exercise by pursuing leisure time physical activity on non-CRP 
days. Meijer et al. (102) used a pedometer to study the activity patterns of sedentary seniors who 
participated in a structured exercise three times a week at a moderate intensity for 12 weeks. 
Although the training program significantly increased physical fitness, it had no effect on total 
daily physical activity as the training activity was compensated for by a decrease in activity on 
non-training days. This outcome was not evident in the present study as experimental patients 
walked approximately 1.25 more miles per day above baseline levels on CRP and non-CRP days 
by the conclusion of the phase II CRP. Approximately 60% of this increase was accomplished 
via aerobic steps and they averaged 14 minutes of continuous walking on non-CRP days. Thus, it 
appears that experimental patients were pursuing structured continuous activity on a regular basis 
to enhance their overall activity level on non-CRP days. This result coincides with Richardson et 
al. (128) who reported that when subjects with Type 2 diabetes were given either overall or 
aerobic step count goals to increase their daily activity levels, most participants chose to reach 
their goals by increasing their aerobic steps.  
     Although pedometers cannot measure exercise intensity, previous research examining phase 
III CRP patients activity patterns has shown that the number of daily step counts strongly 
correlated with accelerometer-derived physical activity energy expenditure (r = 0.92, r2 = 0.846, 
p < 0.001) and time spent in moderate-to-vigorous intensity physical activity (r = 0.85, r2 = 0.73, 
p < 0.001) (14). In addition, Tudor-Locke (182) has reported that a minimal stepping rate of 100 
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steps per minute is the lower threshold for moderate-intensity walking in adults. This parameter 
was satisfied by the experimental group, which averaged 109 steps per minute while performing 
aerobic steps on non-CRP days. Thus, it is likely that the experimental patients were performing 
additional physical activity at moderate intensity levels and durations commonly associated with 
improvements in primary risk factors and reductions in cardiac as well as overall mortality (25, 
78, 182). 
     In the experimental group, average daily step counts improved from 4,085 at baseline to 6,739 
by the conclusion of the phase II CRP, a 65% absolute increase in daily steps. Thus, they 
improved from the ‘sedentary’ designation to the ‘low active’ designation proposed by Tudor-
Locke and Bassett (181). These authors noted that an increase of 2,500 steps/day is associated 
with favorable health outcomes, which the experimental patients achieved for their average daily 
step counts (e.g., 2,653). Previous epidemiology studies have reported that increases in physical 
activity and/or functional capacity decreases the risk of cardiac and all-cause mortality for 
individuals with established CHD (16, 71, 187). Interestingly, the increase in step counts for the 
experimental group corresponds with the results of a recent meta-analysis of pedometer based 
studies. The authors examined the use of pedometers to enhance habitual activity levels and 
quantified that the average increase in daily step counts is 2,491 for pedometer users versus 
control subjects (30). In addition, the preliminary results (at 6 months of a 12 month 
intervention) of a home based CRP program indicate that experimental patients averaged 2,400 
steps/day more than the controls while demonstrating significantly lower LDL levels, systolic 
blood pressure and waist circumference versus controls (76). 
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Activity levels on CRP days 
 
     The experimental and control patients demonstrated a significant increase (p < 0.01) in their 
overall steps and aerobic steps for weeks 2-7 of the phase II CRP versus baseline. This result is 
to be expected since participants in phase II CRP are encouraged to gradually increase their 
exercise intensity and duration as they progress through the program (3). 
     At the conclusion of the phase II CRP, all subjects were averaging 2,135 more steps on CRP 
days and 65% of this activity increase was due to additional aerobic steps. Aerobic steps were 
performed at a pace of 114 steps/minute on CRP days. Thus, it appears that patients walked at a 
similar pace whether supervised or unsupervised (i.e., non-CRP days). It is important to note that 
although the experimental subjects were averaging approximately 7,200 steps/day on CRP days, 
this activity level would not meet the activity guidelines for this population (16, 71, 153). This 
concurs with a previous study which concluded that the majority of phase II CRP patients were 
not performing adequate activity on days they attend a phase II CRP based on their caloric 
expenditures (140). 
Step counts associated with changes in coronary artery lesions 
 
     In the only randomized clinical trial examining the activity patterns of phase III CRP 
participants, Izawa et al. (80) examined the activity patterns of 50 patients, who had just 
completed six months in a phase II CRP in Japan. Subjects were assigned to a self-monitoring 
approach (SMA) or control group. Baseline daily step count values were 6,564 for the SMA 
versus 6,282 for the control group, respectively. During the next six months, the SMA monitored 
their activity levels using a LifeCorder pedometer and recorded them in an exercise log. Both 
groups regularly participated in phase III CR exercise sessions. At the conclusion of the study, 
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the SMA group’s mean daily step counts were 10,458 + 3,310 versus 6,922 + 3,192 in the 
control group (80). These results may be indicative of the changes in activity levels that could be 
attained if the experimental patients in the present study who completed the phase II CRP 
continued to be progressed during the first three months of phase III CRP enrollment. 
     Previous research on individuals with CHD used arteriograms to establish the amount of 
physical activity required for effective secondary prevention of CHD. Subjects who expended 
1,000 kcal/week experienced progression in their coronary lesions, while those expending 1,500 
kcal/week had no changes and patients expending 2,200 kcal/week demonstrated a slight reversal 
in coronary lesions (69, 112). Recently, Ayabe et al. (14) examined 77 subjects enrolled in a 
phase III CRP to determine the accelerometer (e.g., Lifecorder) based daily steps counts required 
to expend 1,000, 1,500 and 2,200 kcal/week. Overall, average daily step counts were 6,752, with 
8,499 steps accumulated on phase III CRP days and 5,491 steps on non- phase III CRP days. The 
average daily step counts which corresponded to 144, 214 and 314 kcal/day (reflective of weekly 
values of 1,000, 1,500 and 2,200 kcal, respectively), were 5,046, 6,470 and 8,496 steps/day, 
respectively. Therefore, the authors concluded that daily step counts of 6,500 and 8,500 
correspond to the physical activity levels associated with arresting coronary artery lesion 
progression and reversing it (69, 112).  
     Experimental patients were averaging 6,739 steps/day at the completion of the phase II CRP, 
which might indicate they were performing an adequate amount of activity to halt the 
progression of their coronary lesions. It is also likely that this group improved their 
cardiorespiratory fitness (CRF) level, a variable that is inversely associated with CHD and all 
cause mortality (5, 25, 187). Additional support is provided for this inference based on the fitness 
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levels of CRP participants when they begin a phase II CRP. Although CRF was not measured in 
the present study, an average VO2max of 15 and 19 ml ·  kg-1 ·  min-1 for women and men, 
respectively, has been reported for this population (5). Thus, moderately paced walking would be 
performed at a high percentage of VO2max. For instance, a woman walking at a pace of 2.5 mph is 
equivalent to 2.9 METs or 10.15 ml ·  kg-1 ·  min-1 which is approximately 70% of her VO2max. 
Regarding men, a walking speed of 3.5 mph would yield the equivalent relative exercise 
intensity. The experimental subjects were consistently performing continuous exercise and likely 
doing so at moderate exercise intensities. This statement is supported by the fact that they 
averaged 15 minutes of aerobic activity at a step rate of 109 steps/minute, which is considered 
moderate intensity activity (182). Consistently performing this volume of activity would be 
likely to improve their VO2max. Previous research has indicated that the magnitude of training-
induced increases in peak VO2 has been shown to independently predict a decrease in 
cardiovascular mortality as well as coronary lesions (147, 187). 
Study limitations 
 
     One limitation of this study is the inability of pedometers to measure non-ambulatory activity, 
such as cycling, arm ergometry and weight lifting. Although walking is the most feasible and 
popular activity for seniors (151), CRPs commonly employ a series of ergometers (e.g., cycle 
and seated stepper ergometers) that involve leg movements that are not accurately measured by 
pedometers (176, 180). During a typical CR exercise session, patients may spend up to 40% of 
their exercise time on these ergometers which leads to an underestimation of their physical 
activity on CRP days. A second limitation is that pedometers cannot accurately estimate caloric 
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expenditure (176, 180). Thus, any discussion of whether proposed step counts are associated 
with changes in coronary artery occlusion is speculative.  
Conclusion 
 
     In conclusion, the present study quantified the amount of physical activity performed by 
patients when they enter a phase II CRP as well as their activity changes during the course of the 
program. Furthermore, activity levels were divided into intermittent and aerobic designations. 
The results demonstrated that the use of a pedometer, coupled with a step count diary and 
individual goals leads to a significant increase of approximately 2,400 steps/day. There were 
increases in overall and aerobic step counts on non-CRP and CRP days for the experimental 
group. The use of pedometers and step count goals can complement traditional phase II CRPs to 
provide a novel strategy for self-monitoring and improving daily activity levels. Future research 
using pedometers should determine whether changes in risk factors and/or coronary blockages 
(using arteriograms) are associated with changes in activity patterns. The results could provide 
more definitive evidence that increasing daily step counts results in significant improvements in 
CHD management.  
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Appendix A: Script for orientation and the provision of the pedometer 
 
 
► At the orientation, please note the following instructions to ensure that the patient is accurately 
monitoring the number of steps they take in their daily lives. 
• The purpose of the study is to learn the total number of steps that patients take each day 
they are enrolled in the Mercy CRP. 
• As soon as you wake up each morning, put the pedometer in your pant pocket (without 
the clip). If they do not have a pant pocket, place the pedometer in the provided belt clip 
and wear it at your waist at the midline of the thigh. I will demonstrate how the 
pedometer should be properly worn. 
• The step counter should be worn during all hours, except when bathing or sleeping. 
• Just before you go to bed each night, please remove the pedometer. 
• Repeat these procedures throughout your enrollment in the Mercy CRP 
 
► After reviewing the informed consent and ensuring that it has been initialed and dated on each 
page, please note that participation in the study is voluntary and that they should contact their 
physician if they have any health related problems or Michael F. Shipe (471-3302) if they have 
any questions about participation in the study. Subjects should be given a copy of the signed 
consent form. 
 
► At the orientation, each eligible patient who agrees to participate in the study and has signed 
an informed consent needs to be given a pedometer. During the first six months of the study, 
individuals enrolled in the morning sessions should be given a pedometer in which they can view 
the number of steps they take daily as well as a calendar. They should be encouraged to keep the 
calendar on their night stand so they are prompted to record their steps each night. The night 
stand would also be a good place to leave the pedometer at night. If they don’t have a night 
stand, encourage them to designate a place to store it consistently. During the first six months of 
the study, patients enrolled in the afternoon class will be given a blinded pedometer in which 
they cannot view their step counts and thus they will not need a calendar. After six months, the 
experimental and control participants will be switched regarding morning and afternoon CRP 
participation.  
 
► If they forget to wear the pedometer, they simply need to note that fact on their calendar. Also, 
they need to bring their calendar with them each Wednesday, so the principal investigator can 
note they are recording their steps, during the education class. 
 
► Subjects in the intervention protocol should only be given the pedometer and a calendar 
during their first week of enrollment in the study. Thereafter, the principal investigator is 
responsible for encouraging patients to begin increasing their step count 5-10% above their 
current daily physical activity levels on non-CRP days for the next two weeks of CRP 
enrollment. Eventually, if they tolerate the additional exercise well, subjects will be encouraged 
to increase their daily step counts an additional 5-10% per day on non-CRP days until they 
average approximately 2,000 more steps day (approximately 1 mile) above their baseline values. 
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► Each patient will be sent a report detailing their step counts throughout their enrollment in the 
Mercy CRP. Further, this report will address whether they pursue adequate physical activity that 
adheres to the CDC/ACSM recommendations. Previous research has shown that these levels of 
physical activity are associated with significant reductions in morbidity and mortality for 
individuals with documented coronary heart disease. 
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Appendix B: Patient Information/Consent Form 
 
The use of pedometers by cardiac rehabilitation program participants to be conducted at 
 
Baptist Hospital of East Tennessee  St. Mary’s Health System, Inc.                     
137 Blount Avenue  900 E. Oak Hill Avenue                                 
Knoxville, TN  37920  Knoxville, TN 37917                        
    
Principal Investigator: Michael F. Shipe 
Sub-investigator: David Bassett, Jr, Ph.D. 
 
PURPOSE: 
The purpose of this study is to use pedometers to examine the physical activity patterns in adults 
who participate in the cardiac rehabilitation programs (CRP) provided by the Mercy Health 
partners at either location noted above.  
 
PROCEDURES: 
You will be asked to carry a pedometer, which measures the number of steps you take each day, 
during your enrollment in the CRP. Based on your fitness level and medical history you will be 
encouraged to walk an additional half mile to 1.5 miles on days you do not attend the CRP, 
which is standard practice. You may also be required to write down the number of steps you take 
a day on an exercise log, which will be provided to you.  
 
POSSIBLE RISKS: 
It is considered an appropriate activity for CRP participants to engage in unsupervised 
intermittent and continuous walking at low to moderate exercise intensities (e.g., 2-3 mph) which 
are not associated with a greater incidence of heart attacks for individuals diagnosed with heart 
disease. In order to minimize the possibility of adverse heart events during walking, you will be 
instructed on general precautions to observe while walking on days you do not participate in the 
CRP. You will be instructed to increase your exercise frequency (e.g., days/week) and duration 
(e.g., time) gradually.  
 
VOLUNTARY PARTICIPATION: 
Participation in this study is voluntary. No compensation for participation will be given. You are 
free to withdraw your consent to participate in this study at any time without prejudice to your 
subsequent care. Refusing to participate will involve no penalty or loss of benefits. You are free 
to seek care from a physician of your choice at any time. If you do not take part in or withdraw 
from the study, you will continue to receive care.  
 
BENEFITS: 
If you agree to take part in this study, there may or may not be direct benefit to you. In general, 
the benefits of participating in a regular walking program include: lowering your blood pressure, 
blood sugar as well as better weight management. Further, regular exercise decreases the risk of 
future of cardiac events, surgeries and additional heart attacks. 
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ALTERNATIVES: 
You may elect not to participate in this study or pursue a regular walking program. 
 
COMPENSATION: 
No compensation is available for participating in this study. Also, no compensation is available 
for a physical or psychological injury which might occur as a result of this study. While medical 
care will be available should an injury occur you will be billed for the costs of providing this 
care.  
 
CONFIDENTIALITY: 
Your hospital records, doctors' office records, laboratory, operating room and cardiac 
rehabilitation records may be reviewed and audited by representatives of the Mercy Health 
partners and the University of Tennessee. The results of this study may be reported in publication 
or presentations although your identity will not be disclosed. 
 
PERSONAL HEALTH INFORMATION: 
Your medical records will be kept as confidential as possible within the limitations of state and 
federal law. Federal Privacy Regulations require that you authorize the release of any health 
information that may reveal your identity. The persons and entities that you are authorizing to 
use or disclose your individually identifiable health information may include the principal 
investigator, the cardiac rehabilitation staff or the Mercy Health partners. In order to analyze the 
data collected during this research study, all of the health information generated or collected 
about you during this study may be inspected by the Office of Human Research Protection 
(OHRP), the Department of Health and Human Services (DHHS) agencies, the Institutional 
Review Board of Mercy Health partners or the University of Tennessee. Because of the need to 
release information to these parties absolute confidentiality cannot be guaranteed. Once your 
personal health information is released it may be re-disclosed, at which point your health 
information will no longer be protected by federal privacy regulations. The results of this 
research may be presented at meetings or in publications; however, your identity will not be 
disclosed in those presentations. By signing this informed consent form, you are authorizing such 
access to your medical records. This authorization will have no expiration. You can discontinue 
this authorization in writing to Michael F. Shipe. If you discontinue your authorization, you will 
also discontinue your participation in this study. 
 
CONTACT PERSON: 
If you have any questions about your rights as a participant in this study, about the study itself or 
if you have any problems or complaints or study related injuries, you may call Mrs. Candy 
Robertson, the Mercy Health partners Institutional Review Board Coordinator at (865) 549-4150 
or Brenda Lawson, Compliance Officer, at the University of Tennessee Office of Research at 
(865) 974-3466. 
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PATIENT CONSENT: 
I agree to voluntarily participate in the study described above. This consent is given based on the 
verbal and written information provided to me. The principle investigator has told me that I am 
medically and physically qualified to participate in this study. I am free to ask questions at any 
time. I may seek information from any source which might help my understanding of this study.  
I have the option of refusing to participate or to withdraw from the study at any time without 
incurring any penalty or loss of benefits otherwise available to me, including medical care at this 
institution.  
 
Michael F. Shipe or the Office for Human Research Protections (OHRP) may take me off the 
study if required to guarantee that my best interests will be served. If I encounter medical 
problems or complications I have been given the telephone number of the East Tennessee Heart 
Consultants (865) 673-9656 and my physician. If I have any questions about the study, I can 
contact Michael F. Shipe at 471-3302. 
 
By consenting to participate in this study, I understand that I am responsible for carrying out 
instructions and that I must relate to Michael F. Shipe or other study personnel any information 
that might be relative to the study, such as any side effects of a treatment or procedure. Any 
reluctance I might have to continue in the study must also be reported. Any new information 
regarding the study and any treatment it involves which might affect my willingness to continue 
my participation in the study will be related to me in an appropriate way. I will receive a signed 
and dated copy of this consent form. 
 
 
_____________________________    __________________________ 
Signature of Patient     Date 
 
_____________________________  __________________________ 
Signature of Witness    Date 
 
_____________________________    __________________________ 
Signature of Investigator   Date 
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Appendix C: Step count log instruction for experimental subjects 
 
      At the end of each day please record the number of total steps you have taken. The pedometer 
should display the number of steps you have taken for a given day. Please record your step count 
values for the correct day on the calendar listed below. It may be easier to ensure that you keep 
an accurate record of your daily steps by keeping your exercise log on your nightstand. If you do 
so, you will be prompted to record your steps each night before you go to bed. You may also 
want to designate your nightstand as the area in which you place your pedometer at the end of 
each evening. Therefore, you have a designated, convenient area to place it when you are not 
wearing it. By doing so, you will reduce the chance you will lose the pedometer. Also, the 
pedometer will be visibly present on your nightstand and its appearance can prompt you to wear 
it at the beginning of each morning. If you are having any type of difficulty with your pedometer,  
please contact Michael Shipe at 865-471-3302. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
February 2008 
Sunday Monday Tuesday Wednesday Thursday Friday Saturday 
  1 2 3 4 5 
6 7 8 9 10 11 12 
13 14 15 16 17 18 19 
20 21 22 23 24 25 26 
27 28 29 30 31   
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Appendix D: Summary report of participant’s step counts 
 
Dear Mr. or Mrs. __________ , 
     Initially, I want to thank you for your willingness to participate in my dissertation research. 
To date, there has never been a research study which has objectively quantified the activity 
patterns of individuals during their enrollment in Phase II cardiac rehabilitation program (CRP). 
Thus, the results of my study (e.g., your exercise patterns) will likely be used to help design 
appropriate exercise prescriptions to improve the clinical outcomes for other cardiac 
rehabilitation programs. The objective of my research is to determine your activity levels, 
specifically the number of step counts, on the days you attend cardiac rehabilitation versus the 
days you do not. The results for your average overall and aerobic steps each day of the week 
during your 12 week enrollment is presented in the graph below. Please keep in mind that 
walking approximately 2,000 steps is equivalent to approximately 1 mile. Thus if you walk 5,000 
steps in a day, then you would have walked 2.5 miles (5,000/2,000 = 2.5). Also, you will see that 
there is a designation for overall steps, which is the total number of steps you completed in a 
given day and also a designation for aerobic steps. Aerobic steps are only accumulated when you 
walk for at least 10 minutes without stopping. Thus, if you walked for 8 minutes consecutively 
and then stopped for more than a minute then you would have only accumulated overall steps. 
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     As indicated by the graph, you achieved the highest number of overall and aerobic steps on 
the days you attended the Mercy CRP (e.g., M, W, F) and averaged approximately 7,500 steps on 
those days. Friday was the highest day for overall steps, which is not surprising given that is the 
day you reported that you perform the majority of your yardwork. On Mondays, Wednesdays 
and Fridays you accumulated the most aerobic steps, approximately 3,000, which is attributable 
to your regular particpation in the Mercy phase II CRP on those days. It is important to note that 
pedometers are designed to accurately measure the steps you take each day and do not accurately 
measure the activity you performed using the cycle or seated stepper ergometers (e.g., bicyele or 
NuStep®). Thus, you could possibly add another 1,000-1,500 steps to your overall and aerobic 
steps on the days you attended the Mercy phase CRP to account for this shortcoming.  
     A common pattern in the general population is reflected in your activity patterns on the 
weekend. Note that although your activity patterns on Saturday are similar to your results during 
the week, Sunday is a different story. Prior physcial activity monitoring research indicates that 
individuals are markedly less active on Sunday versus any other day of the week and you were as 
well. Yet if you simply designate and take the time to walk for 10 to 15 minutes each Sunday, 
you could easily elevate your step counts on this day by 1,000-1,500 steps. 
     The next graph depicts your average overall and aerobic step counts on the days you attended 
the Mercy phase II CRP (e.g., M, W and F) during each of your 12 weeks in the program. As 
before, your steps are divided between overall and aerobic steps. 
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     As you can see, you began with averaging 4,000 steps per day on MWF during your first 
week in the CR program and progressed to averaging over 10,000 steps per day on MWF 12 
weeks later! In essence, your physical activity levels improved by approximately 250%; certainly 
a commendable accomplishment. You may note that there was a significant drop at week 5 
which is attributable to the eye surgey you had that week. As you are aware, it is relatively easy 
to accumulate high step counts when your exercise in a structured environment where you are 
expected to exercise 45-50 minutes three times a week. Yet what happens when you choose to 
exercise on your own, with only a pedometer and exercise log to hold you accountable? The last 
graph answers this question as it demonstrates your average overall and aerobic step counts on 
the days (T, R, Sa. and Su.) you did not attend the Mercy phase II CRP. 
 
      
     You began the CRP by averaging 3,400 steps on your non-CRP days per week and improved 
to 8,000 steps; a 135% improvement! Again, a qualified success in enhancing your physical 
activity levels. And just think if you are consisently able to improve your steps count on Sundays 
you would average almost 9,000 steps/day. So, what does all of this mean? First of all, it is 
improtant keep in mind that the benefits of exercise mirror the effects of medicine. The more 
consistent, the greater and the longer you perform regular aerobic exercise, the greater the effect. 
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     Regular aerobic exercise provides a multitude of health benefits that will enhance your ability 
to manage your coronary heart disease (CHD) effectively. Specifiically, regular aerobic exercise 
is associated with a stronger and more efficient heart, lower blood pressure, an improved lipid 
profile, better weight management and provides a powerful manner in which to reduce your 
blood sugar levels.  
     Your greatest concern may be how to positively effect the blockages you have in your 
coronary arteries and how much exercise is required to do so. At this time, research indicates that 
individuals who have established CHD demonstrate increased coronary artery blockages when 
they expend the energy equivalent of walking on average 5,000 steps/days. In essence, 
individuals walking this amount experienced more blockages in their coronary arteries. 
Individuals with established CHD, who expended the energy equivalent of walking on average 
6,500 steps/day often demonstrated no change in their cornary artery blockages; they didn’t get 
any better nor did they get any worse. Finally, indiviudals who expended the energy equivalent 
of walking on average 8,500 steps/day were likely to exhibit a reduction in the blockages of their 
coronary arteries. In other words, they were able to miminally reverse the amount of CHD they 
exhibited! The take home message is that if you want to increase the chances of positively 
affecting your CHD you will need to accumulate 8,500 steps/day or walk approximatley 4.25 
miles each day.  
     The good news is that you were averaging approximately 6,800 steps/day when you 
completed the Mercy phase II CRP as opposed to 3,200 steps/day when you started. At this level, 
the research indicates that you may be expending and adequate amount of energy through 
physical activity to keep your CHD from progressing. The better news is that if you can add a 
15-20 minute walk 5 days a week to your present activity patterns then you may enjoy a 
reduction in the blockages you already have. Please keep in mind that these outcomes are not 
guaranteed and are based on the fact that you will also pursue a heart healthy dietary regimen as 
well. 
     So, where do you go from here? Previous research indicates that the majority of perople who 
complete a CR program and do not join an exercise facility are highly likely to revert back to 
their previous sedentary habits, which would lead to a progression of the CHD process. If you do 
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not want to regularly particpate in a structured exercise program, then here are some tips to 
exercising on your own. 
 
1. Develop a positive outlook regarding physical activity. If you consider exercise a chore, 
drudgery or pain you simply will not continue to do it. A basic principle of psychology is 
that you repeat behaviors you enjoy. Think of exercise as a means to improve you heart, 
combat heart disease or to enhance your ability to play with your grandchildren. Think of 
these things each time you consider skipping an exercise session or quitting exercise 
altogether. Ultimately you must come to the conclusion that regular exercise is a 
fundamental part of a healthy existence and without it you will likely have to rely upon 
medications and surgical procedures to maintain a lower quality of life.  
 
2. Exercise must become a priority in your daily life. Designate a day, time, place and 
amount of exercise you will perform on the days you plan to be physically active. Treat 
your physical activity plan as if it is a crucial business meeting you could not afford to 
miss. If exercise is something you plan to do at the end of the day when you are done 
with everything else, then guess what? You will never get done with everything else. 
 
3. Set a SMART goal for your physical activity program. A specific, manageable, 
attainable, realistic, time based goal can assist you in attaining your exercise goals. For 
instance, your goal is to progress in your exercise capacity until you can walk 3 miles in 
your neighborhood in 50 minutes five times a week at 7 a.m. in the morning.  
  
4. Social support is a must to keep you exercising. Involving a spouse in your exercise 
program has been shown to increase long-term exercise compliance by 50% percent. If 
not your spouse, then ask a friend or another relative to accompany you on your walks so 
that they become social and more enjoyable. And remember when you enjoy a given 
activity you are more likely to repeat it. 
 
5. Don’t become discouraged if you are unable to reach your exercise goals as quickly as 
you would have liked. Unforeseen obstacles will arise and you will undoubtedly 
experience days, if not weeks, when you do not exercise. During these times, it is 
important to reflect upon why you haven’t exercised regularly. Look at the four tips 
above and make sure you implement each one to increase the chances you will exercise 
more consistently in the future. 
 
      Again Mr. or Mrs. __________ , I want to thank you for the time and effort you have 
contributed to the completion of my dissertation. If you have any questions about this report or I 
can be of service concerning any questions you may have about your exercise regimen, please 
contact met at 865- 471-3302. 
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